# **New Jersey Institute of Technology [Digital Commons @ NJIT](https://digitalcommons.njit.edu?utm_source=digitalcommons.njit.edu%2Ftheses%2F574&utm_medium=PDF&utm_campaign=PDFCoverPages)**

[Theses](https://digitalcommons.njit.edu/theses?utm_source=digitalcommons.njit.edu%2Ftheses%2F574&utm_medium=PDF&utm_campaign=PDFCoverPages) and Dissertations and [Theses and Dissertations](https://digitalcommons.njit.edu/etd?utm_source=digitalcommons.njit.edu%2Ftheses%2F574&utm_medium=PDF&utm_campaign=PDFCoverPages) and Theses and Dissertations and Theses and Dissertations and  $\Gamma$ 

Spring 2004

# Mathematical modeling of transient state transdermal drug delivery

Alison Nickol Weltner *New Jersey Institute of Technology*

Follow this and additional works at: [https://digitalcommons.njit.edu/theses](https://digitalcommons.njit.edu/theses?utm_source=digitalcommons.njit.edu%2Ftheses%2F574&utm_medium=PDF&utm_campaign=PDFCoverPages) Part of the [Chemical Engineering Commons](http://network.bepress.com/hgg/discipline/240?utm_source=digitalcommons.njit.edu%2Ftheses%2F574&utm_medium=PDF&utm_campaign=PDFCoverPages), and the [Pharmaceutics and Drug Design](http://network.bepress.com/hgg/discipline/733?utm_source=digitalcommons.njit.edu%2Ftheses%2F574&utm_medium=PDF&utm_campaign=PDFCoverPages) [Commons](http://network.bepress.com/hgg/discipline/733?utm_source=digitalcommons.njit.edu%2Ftheses%2F574&utm_medium=PDF&utm_campaign=PDFCoverPages)

#### Recommended Citation

Weltner, Alison Nickol, "Mathematical modeling of transient state transdermal drug delivery" (2004). *Theses*. 574. [https://digitalcommons.njit.edu/theses/574](https://digitalcommons.njit.edu/theses/574?utm_source=digitalcommons.njit.edu%2Ftheses%2F574&utm_medium=PDF&utm_campaign=PDFCoverPages)

This Thesis is brought to you for free and open access by the Theses and Dissertations at Digital Commons @ NJIT. It has been accepted for inclusion in Theses by an authorized administrator of Digital Commons @ NJIT. For more information, please contact [digitalcommons@njit.edu](mailto:digitalcommons@njit.edu).

# Copyright Warning & Restrictions

The copyright law of the United States (Title 17, United States Code) governs the making of photocopies or other reproductions of copyrighted material.

Under certain conditions specified in the law, libraries and archives are authorized to furnish a photocopy or other reproduction. One of these specified conditions is that the photocopy or reproduction is not to be "used for any purpose other than private study, scholarship, or research." If a, user makes a request for, or later uses, a photocopy or reproduction for purposes in excess of "fair use" that user may be liable for copyright infringement,

This institution reserves the right to refuse to accept a copying order if, in its judgment, fulfillment of the order would involve violation of copyright law.

Please Note: The author retains the copyright while the New Jersey Institute of Technology reserves the right to distribute this thesis or dissertation

Printing note: If you do not wish to print this page, then select "Pages from: first page  $#$  to: last page  $#$ " on the print dialog screen



The Van Houten library has removed some of the personal information and all signatures from the approval page and biographical sketches of theses and dissertations in order to protect the identity of NJIT graduates and faculty.

#### **ABSTRACT**

#### **MATHEMATICAL MODELING OF TRANSIENT STATE TRANSDERMAL DRUG DELIVERY**

### **by Alison Nickol Weitner**

In this work, a two-pathway mathematical model for transdermal drug delivery with iontophoresis is presented. The partial differential equations are described and then solved. An alternative, two-pathway, three-layer model is also presented, and the implications of the coefficients within the equation are discussed. Using Franz cell iontophoretic delivery data from three drug substances (amitriptyline HC1, clomipramine HC1, and amitriptyline HC1), the two-pathway model is regressed to determine the diffusion coefficient and the concentration within the skin at the drug reservoir interface. ANOVA analysis indicates a correlation between iontophoretic current and concentration of drug within the stratum corneum.

### **MATHEMATICAL MODELING OF TRANSIENT STATE TRANSDERMAL DRUG DELIVERY**

**by Alison Nickol Weltner**

**A Thesis Submitted to the Faculty of New Jersey Institute of Technology In Partial Fulfillment of the Requirements for the Degree of Master of Science in Pharmaceutical Engineering**

**Department of Chemical Engineering**

**May 2004**

 $\sqrt{}$  $\bigcirc$ 51

#### **APPROVAL PAGE**

### **MATHEMATICAL MODELING OF TRANSIENT STATE TRANSDERMAL DRUG DELIVERY**

**Alison Nickol Weitner**

 $\bar{z}$ 

Dr. Laurent Simon, Thesis Advisor Date Assistant Professor of Chemical Engineering New Jersey Institute of Technology

Dr. Piero Armenante, Committee Member Date Distinguished Professor of Chemical Engineering New Jersey Institute of Technology

Dr. Bozena Michniak, Committee Member Date Associate Professor of Pharmacology and Physiology University of Medicine and Dentistry of New Jersey — New Jersey Medical School

## **BIOGRAPHICAL SKETCH**

**Author:** Alison Nickol Weitner

**Degree:** Master of Science

**Date:** May 2004

#### **Undergraduate and Graduate Education:**

- Master of Science in Pharmaceutical Engineering New Jersey Institute of Technology, Newark, New Jersey, 2004
- Bachelor of Science in Chemical Engineering University of Notre Dame, Notre Dame, Indiana, 2001

**Major:** Pharmaceutical Engineering

To my parents, in deep gratitude for the support and encouragement they have given throughout every step of my education.

 $\bar{z}$ 

#### **ACKNOWLEDGMENT**

**I** wish to express my deepest appreciation to my research advisor, Dr. Laurent Simon, who, with great enthusiasm and patience, has guided me through this project.

Thank you to Dr. Bozena Michniak and Dr. Piero Armenante, who have served as reviewers of this thesis.

Finally, I would like to give very special thanks to Yiping Wang, who has not only provided raw data for my analysis, but has also taken time to share her knowledge of iontophoresis and Franz cell diffusion studies with me.

# **TABLE OF CONTENTS**



## **TABLE OF CONTENTS (Continued)**



# **LIST OF TABLES**

 $\mathcal{L}(\mathcal{A})$  and  $\mathcal{L}(\mathcal{A})$  .



# **LIST OF FIGURES**



#### **CHAPTER 1**

#### **INTRODUCTION**

Transderrnal drug delivery is the practice of delivering a therapeutic chemical substance to the body via the skin. The transdermal route of drug administration is advantageous for a number of reasons. Entry into the general circulation through the skin circumvents hepatic metabolism, the process by which an orally administered drug may be chemically altered before reaching its target organ. Unlike delivery systems which require intermittent dosing, the transdermal route can circumvent fluctuating concentration levels within the blood. A transdermal delivery system can make continuous dosing feasible, thereby achieving steady drug concentrations within the body.

Additionally, transderrnal systems offer great potential for enhanced patient compliance. Applying a transdermal patch is easy and painless. Once applied to the patient's skin, the patch remains in place for an extended period of time, during which a slow, controlled amount of drug is released to the body. The patient receives the needed dose in a manner convenient and non-disruptive to his or her normal activities. Issues resulting from a patient forgetting to take his or her medication or failing to take the medication as directed can be minimized.

While transdermal delivery systems offer great advantages to the consumer, such techniques present formidable challenges to their designers. The necessary development work is extensive. Transdermal drug delivery requires an understanding and application of both pharmacological principles and engineering principles as well. The device must allow the drug to penetrate the barrier properties of the skin, while also achieving a release a rate that suits the patient's needs.

#### **1.1 The Structure of the Skin**

The barrier properties of the skin are innately difficult to overcome. The natural function of skin is to deter foreign substances from entering the body and to prevent necessary fluids and nutrients from escaping the body. To design an effective transdermal delivery system, these barrier properties must be addressed.

The most significant contributor to these barrier properties is the outer-most layer known as the stratum corneum (Bouwstra et al., 2001). The stratum corneum is composed of keratin-filled dead cells known as "corneocytes." The cell membrane of the comeocytes contains a dense, highly impermeable protein layer. Surrounding the corneocytes is a continuous, crystalline lipid bilayer. A common conceptual representation of the stratum corneum is the "brick and mortar" model, named for its similarity in appearance to individual bricks (i.e. the corneocytes) surrounded by mortar (i.e. the lipid regions) (Barry, 1983; Pieper et al., 2003). Although the structure of the lipid bilayer is not easily overcome, its continuity across the stratum corneam makes it a potential route for transport through the stratum corneum (Bouwstra et al., 2001).

Below the stratum corneum is the viable epidermis. The epidermis demonstrates fewer barrier properties than the stratum corneum (Lee et al., 1997). Unlike the stratum corneum, the viable epidermis contains enzymes which can have a metabolic function (Lee et al., 1997). Below the viable epidermis are the capillaries, which can readily

absorb substances from the epidermis into the bloodstream. Once in the bloodstream, the drug substance can be carried to the target organ.

#### **1.2 Methods for Enhancing Drug Penetration Through the Skin**

Due to the difficulty in penetrating the stratum corneum, various means and mechanisms for enhancing transdermal drug delivery have been pursued. Two such methods for overcoming the stratum corneum barrier properties are the use of chemical enhancers and the use of iontophoresis.

#### **1.2.1 Drug Penetration Enhancement Through the Use of Chemical Enhancers**

Chemical enhancers improve transderrnal drug delivery by reducing the resistance of the stratum corneum to the drug molecules. Existing evidence suggests that chemical enhancers operate by disturbing the lipid organization in the stratum corneum. The  $mechanism(s)$  by which the enhancer disturbs the stratum corneam lipid organization depend on the enhancer's chemical structure and affinities. Bouwstra et al. (2001) have theorized several possible mechanisms for disturbing the stratum corneum lipid organization: (a) the enhancer molecules insert themselves sporadically into the lipid lamellae, (b) the enhancer inserts itself between the lamellae layers, thus disturbing the packing of the layers, and (c) the enhancer molecules form an organized, separate phase within the lamella. Additionally, other works have shown how specific types of chemical bonding, such as hydrogen bonding, can effect a change in drug penetration through skin (Hadgraft, 2001; Du Plessis et al., 2002).

Several methods have been used to incorporate chemical enhancers in transdermal drug delivery systems. One approach has been to incorporate the chemical enhancer into the drug formation itself (Harrison et al.; 1996; Fang et al.; 1999; Essa et al., 2004). Another approach has been to incorporate the chemical enhancers as a pretreatment for the skin prior to the application of the drug vehicle itself (Graaff et al.; 2003, Nair and Panchagnula, 2003; Wang et al., 2003). *In vitro* observations show that skin samples treated with a fatty acid prior to application of the drug resulted in increased overall drug penetration (Wang et al., 2003; Nair and Panchagnula, 2003).

#### **1.2.2 Drug Penetration Enhancement Through the Use of lontophoresis**

Another approach to improving transdermal drug delivery is a technique called iontophoresis. In iontophoretic delivery, a small electric current is used to drive the drug molecules across the skin barrier. Jontophoresis is a promising technology that has already received some regulatory approval. Iontocaine $\mathcal{R}$ , an iontophoretic transdermal system developed by lomed Corporation (Salt Lake City, Utah), is currently marketed for the administration of lidocaine HC1, a local anesthetic. Vyteris, Inc. (Fairlawn, New Jersey), in partnership with B. Braun Medical, Inc., is awaiting approval of its own iontophoretic system for transdermal lidocaine delivery. Alza Corporation (Mountainview, California), a subsidiary of Johnson & Johnson, has developed an iontophoretic delivery system known as E-Trans® and has applied the E-Trans® technology to administer fentanyl HC1, an analgesic. The product is now in late-stage development.

Drugs delivered via iontophoresis are typically hydrophilic and ionic. Positively charged drugs are placed at the anode; negatively charged drugs are placed at the cathode. A small battery provides a voltage that drives the drug out of the donor reservoir and into the skin. To complete the electric circuit, a buffer solution is placed in a return reservoir (Junginger, 2002). A diagram is given in Figure 1.1.



**Figure 1.1** Design of an iontophoretic delivery patch. The device consists of a drug reservoir and a return reservoir connected by a battery. The placement of the anode and cathode depends on the charge of the drug being delivered.

#### **1.3** *In Vitro* **Methods for Study and Analysis of Transdermal Drug Delivery**

Studies of fundamental transdermal drug delivery principles are commonly conducted *in vitro,* rather than *in vivo. In vivo* analysis presents myriad complexities, complications, and restrictions that render it unsuitable for basic investigation into mass transfer principles. For example, ethics prohibit conducting *in vivo* studies in humans before sufficient knowledge regarding toxicity or side effects has been gathered. Furthermore, the interpretation of data from *in vivo* testing is more problematic, since other physiological variables may alter or mask the effect of the studied parameter.

*In vitro* studies of transdermal delivery principles are typically conducted in a Franz diffusion cell. A Franz cell consists of two chambers, one of which contains the drug substance and one of which contains the receptor fluid. A small, thin piece of skin

is placed between the compartments, thus allowing the drug substance to penetrate from the donor compartment across the skin to the receptor compartment. Periodically, the drug concentration in the receptor fluid is collected and assayed to determine the quantity of drug transported across the skin. A diagram is given in Figure 1.2.



Figure 1.2 Diagram of a Franz cell apparatus for iontophoretic delivery. The drug and its vehicle are loaded into the donor compartment. The drug diffuses through the skin and into the receptor compartment. In the iontophoretic system shown here, the anode is placed at the donor cell and the cathode at the receptor cell.

Franz cell data analysis is performed by calculating *Q,* the mass quantity of drug accumulated in the receptor cell over time, and then plotting  $Q$  as a function of time  $(t)$ . For most iontophoretic delivery, the *Q* versus *t* plot is nonlinear at initial *t* values but becomes linear at large *t* values. The slope of the linear region, divided by the surface area available for diffusion, represents the flux of the drug through the skin in units of mass per area per time.

Analysis by the graphical method is useful for quantifying and comparing results among individual studies. However, the graphical method alone cannot explain why differences or similarities among a given set of experiments exist. Employing a

mathematical model can enhance the analysis process by offering insight as to the mechanism(s) by which a particular outcome is achieved.

#### **1.4 Applying Mathematical Models to Analyze Transdermal Drug Delivery Data**

In this work, two new models for mathematical analysis of drug delivery through the skin are presented. The models are based on previous work available in the literature. The first model, discussed in Chapter 2, is a one-layer, two-pathway model which characterizes delivery through the stratum corneum. The second model (Chapter 3) is a three-layer, two-pathway model which encompasses delivery from the drug vehicle (i.e. the delivery device) itself to the stratum corneum, and then from the stratum corneum through the viable epidermis and finally to the capillaries.

In Chapter 2, the solutions to the partial differential equations for the one-layer, two-pathway model are presented. In Chapter 4, these solutions are applied to several existing sets of iontophoretic delivery data. Using nonlinear regression software, a series of coefficients corresponding to the diffusion coefficient and the concentration within the stratum corneum at the vehicle-device interface are established. The values for these coefficients are compared and discussed.

#### **CHAPTER 2**

#### **TRANSlENT MODEL FOR A TWO-PATHWAY SYSTEM**

A number of mathematical models have been presented in the literature as a means of describing transdermal delivery data. These models have discussed passive diffusion (Lee and Aldama, 1992; Lee et al., 1996; Mitragotri, 2002; Tezel and Mitragotri, 2003), diffusion assisted through chemical enhancers (Moser et al., 2001), diffusion of solvents through the skin (Pikal, 2001), and diffusion aided through iontophoresis (Kontturi and Murtomaki, 1996; Lim et al., 2002).

The model proposed by Kontturi and Murtomäki (1996) for iontophoretic systems is based on the assumption that parallel pathways are available for drug diffusion in the skin. These routes are referred to as the aqueous and lipid pathways. Drug flux through the skin is thus a function of the flux through each of the two pathways.

Kontturi and Murtomaki present equations to characterize steady flux through the stratum corneum for their two-pathway system. However, the transient state solutions for this model have not yet been developed. In this chapter, the two-pathway model is analyzed and solved for the transient state condition.

#### **2.1 The Kontturi-Murtomäki Two-Pathway Model**

The two-pathway model developed by Kontturi and Murtomaki (1996) considers drug penetration through the stratum corneum to be the product of transport across two separate pathways. These pathways exist in parallel; migration from one path to the other is not addressed.

The two pathways differ based on their composition: one pathway is lipophilic and will take up only neutral molecules. The second pathway is hydrophilic and will readily take up charged ions as well as neutral molecules.

An important assumption in Kontturi and Murtomäki's work is that enhancement of delivery due to iontophoresis impacts the aqueous pathway exclusively. The rationale for this assumption is that only the aqueous pathway can carry an electrical current. In the Kontturi-Murtomäki model, enhancement of flux through the aqueous pathway due to iontophoresis is mathematically represented by a factor of *E .* The value of *E* increases with increased iontophoretic current.

As a general principle, the total flux through parallel pathways is equal to the sum of the fluxes through the individual paths, scaled by their surface areas. Thus, if  $J_a$  and  $J<sub>l</sub>$  are defined as fluxes through the aqueous and lipid pathways, respectively, then the total flux across the skin is equal to the sum of these fluxes multiplied by the fraction of their respective surface areas.

In the presence of iontophoresis, the effective flux through the aqueous pathway is increased. The surface area fraction consisting of the aqueous pathway is defined as  $\varepsilon$ (Kontturi and Murtomäki, 1996). It thus follows that the surface area fraction consisting of the lipid pathway is  $1-\varepsilon$ . As such, in terms of the enhancement factor E, the total flux in the skin due to iontophoresis  $(J_i)$  may be defined as:

$$
J_{if} = E^* \varepsilon^* J_a + (1 - \varepsilon) J_i \tag{2.1}
$$

Kontturi and Murtomäki's model applies to transport through the stratum corneum only. The boundary conditions assume that the drug is applied to the skin in a wellstirred reservoir. The bulk concentration of this reservoir,  $C_b$ , partitions into the skin

layer according to the partition coefficient *P.* Furthermore, Kontturi and Murtomaki's analysis is generalized such that bulk solution in the donor reservoir may contain a drug substance in both ionized and non-ionized forms. A parameter  $\alpha$ , defined as the fraction of drug present in the non-ionized form, accounts for this possibility. A diagram of the system analyzed by the Kontturi-Murtomäki two-pathway model is given in Figure 2.1.



**Figure 2.1** Diagram of transport through the stratum corneum as characterized by the two-pathway model. The darker regions in the stratum corneum represent the lipid pathway; the lighter regions represent the aqueous pathway.

Through their analysis, Kontturi and Murtomäki show that drug flux through the lipid pathway of the stratum corneum may be represented as:

$$
J_l = \frac{\alpha C_b k_D}{1 + \frac{k_D L}{D, P}}
$$
\n(2.2)

where  $D_i$  is the diffusion coefficient for the drug in the lipid path and  $L$  is the length of the diffusion pathway, taking into account both tortuosity and membrane thickness. Embedded in this result are two boundary conditions. The concentration of drug at the

drug reservoir-skin interface is dependent upon the lipid pathway partition coefficient, the concentration of drug in the bulk, and the fraction of the bulk drug in the non-ionized form. (The surface area fraction of the lipid pathway  $(1 - \varepsilon)$  is omitted from the final result as a simplification, since the quantity is taken to be very close to unity. Kontturi and Murtomäki use a value of  $10^{-4}$  for  $\varepsilon$ .)

Hence, the steady state flux at this interface (i.e. at  $z = 0$ ) is represented as  $D_1 \alpha P C_b / L$ . At the opposite end, transport out of the stratum corneum skin layer and into the viable epidermis is governed as a desorption process obeying first-order kinetics with a rate constant of  $k<sub>p</sub>$ .

The flux through the aqueous layer is given as:

$$
J_a = \varepsilon D_a \frac{C_b}{L} \tag{2.3}
$$

where  $D_a$  is the drug diffusion coefficient in the aqueous path. The concentration boundary condition of the aqueous layer at the reservoir-stratum corneum interface is equal to  $C_b$ . For the aqueous layer, the concentration boundary condition at the stratum corneum-epidermis interface is taken to be 0, due to the infinite sink approximation.

The boundary conditions for the lipid and aqueous pathways differ. Unlike the lipid layer, Kontturi and Murtomäki do not multiply the skin concentration for the aqueous pathway by the quantity  $\alpha$ , because both the ionized and non-ionized forms of the drug are permitted to pass through the aqueous pathway.

The boundary conditions at  $z = L$  (i.e. the stratum corneum/viable epidermis interface) differ for the two pathways as well. Kontturi and Murtomäki explain that the viable epidermis is characterized by polarity similar to that of water. Because the aqueous layer and the viable epidermis are alike with respect to polarity, desorption from the aqueous pathway to the epidermis should have a time scale much faster than that of the diffusion process through the aqueous path itself. Thus, infinite sink conditions is an appropriate approximation for the aqueous path.

The difference in polarity between the lipid pathway and the viable epidermis, however, poses a problem to which the perfect sink approximation cannot be applied. Based on empirical observations (Kontturi and Murtomaki, 1996), Fickian diffusion alone cannot account for lipid pathway diffusion. To summarize Kontturi and Murtomaki's argument (1996), if the perfect sink condition applied to the stratum corneum-viable epidermis interface for the lipid path as well as the aqueous path, then partition from the lipid layer of the stratum corneam to the viable epidermis would increase or decrease only with a single partition coefficient. Furthermore, partition of a highly lipophilic drug into the lipid layer from the drug reservoir would have to be fast as well, due to the similar polarity between the drug and the lipophilic layer. As such, the only rate limiting parameter for the lipid pathway would be the diffusion coefficient through the pathway itself. Empirical data does not match this conclusion. Thus, a kinetic process must occur at the stratum corneum-viable epidermis interface to account for this problem. Kontturi and Murtomaki capture the effect of this transfer between skin layers in terms of a first order kinetics model with a rate constant of  $k_p$ .

#### **2.2 Partial Differential Equations Describing the Two-Pathway System**

The analysis performed by Kontturi and Murtomaki (1996) is based on Fickian diffusion and application of suitable boundary conditions. However, the flux equations in the Kontturi-Murtomäki analysis do not address the transient state conditions. Kontturi and Murtomäki's results are only applicable to steady state, constant flux conditions, and thus only apply when the large time approximation is employed.

Understanding the drug concentration profile for transient conditions, however, is important for several reasons. For example, in the case of high potency drugs, the quantity delivered to the plasma prior to achieving steady state flux may lead to toxicity problems. In the delivery of rescue medications, the time required to achieve an adequate plasma concentration may be more critical than the time required for steady state flux through the skin. Additionally, studying the dynamics of the system prior to the steady state conditions can help explain the rate limiting steps in the delivery process. This knowledge, in turn, can be utilized to improve the system design.

As previously explained, diffusion through the aqueous layer is entirely due to Fickian diffusion. The general equation for Fickian diffusion is:

$$
\frac{\partial C_a}{\partial t} = D_a \frac{\partial^2 C_a}{\partial z^2} \tag{2.4}
$$

To this equation, the enhancement factor *E* is added to account for iontophoresis, thus obtaining:

$$
\frac{\partial C_a}{\partial t} = E^* D_a \frac{\partial^2 C_a}{\partial z^2}
$$
\n(2.5)

In this equation, *z* represents the linear direction over which the diffused substance travels, and  $C_a$  represents the concentration within the aqueous pathway of the stratum corneum at a given location  $z$  and time  $t$ . The drug reservoir-delivery device interface is defined as  $z = 0$ , and the delivery device-viable epidermis interface is defined as  $z = L$ .

The boundary conditions for the aqueous layer, at any time  $t$ , are given as:

$$
C_a(0,t) = C_b \tag{2.6}
$$

$$
C_a(L,t) = 0\tag{2.7}
$$

and the initial condition is given as:

$$
C_a(z,0) = 0\tag{2.8}
$$

The boundary conditions assume fast diffusion in the delivery device as compared to the skin. Thus, the drug concentration on the drug reservoir side at  $z = 0$  remains constant.

The diffusion through the lipid layer during iontophoresis is also modeled by Fickian diffusion. Since iontophoresis enhances only the aqueous pathway, the partial differential equation for the lipid layer is analogous to the equation describing passive diffusion except that it does not contain the enhancement factor. The concentration in the lipid layer is thus described as:

$$
\frac{\partial C_l}{\partial t} = D_l \frac{\partial^2 C_l}{\partial z^2}
$$
\n(2.9)

The initial condition for the lipid layer is analogous to initial condition for the aqueous layer (i.e. no drug is present in the stratum corneum at  $t = 0$ ).

$$
C_1(z,0) = 0 \tag{2.10}
$$

Applying the boundary conditions established by Kontturi and Murtomäki (1996), as introduced in Section 2.1, the concentration of the lipid layer at the device-skin interface at any time:

$$
C_1(0,t) = \alpha PC_b \tag{2.11}
$$

$$
-D_l \frac{\partial C_l(z,t)}{\partial z}\bigg|_{z=L} = \frac{k_D}{P} C_l(L,t) \tag{2.12}
$$

#### **2.3 Solving the Partial Differential Equations for Flux and Accumulation**

Generally, transdermal systems are characterized in terms of the flux they provide. Flux, represented by  $J_a$  and  $J_i$  for the aqueous layer and the lipid layer, respectively, is expressed in units of mass of drug per area per time. As defined by the equations, flux is a function of time. However, as noted in Section 1.3, steady state flux is achieved for substantially large *t* values.

For each pathway, the quantity of drug accumulated in the receptor cell over time is a function of the diffusion coefficient, the surface area available for diffusion, and the concentration gradient at  $z = L$ . These equations for the aqueous and lipid layers, respectively, may be represented as:

$$
\frac{dQ_a(t)}{dt} = -E\varepsilon AD_a\left(\frac{\partial C_a}{\partial z}\right)_{z=L}
$$
\n(2.13)

$$
\frac{dQ_i(t)}{dt} = -(1 - \varepsilon)AD_i \left(\frac{\partial C_i}{\partial z}\right)_{z=L}
$$
\n(2.14)

The total surface area of skin available for diffusion is *A.* As introduced in Section 2.1, the parameters  $\varepsilon$  and  $1-\varepsilon$  represents the fraction of the skin surface area that is composed of the aqueous and lipid layers, respectively.

When the above equations are normalized for area, the resulting expression is the flux in units of mass per area per time:

$$
J_a(t) = -E * D_a \left(\frac{\partial C_a}{\partial z}\right)_{z=L}
$$
 (2.15)

$$
J_l(t) = -D_l \left(\frac{\partial C_l}{\partial z}\right)_{z=L}
$$
 (2.16)

Solving Equation 2.15 for the aqueous layer, the cumulative amount of drug penetrated through the aqueous pathway in the skin per unit area, as a function of time, becomes:

$$
Q_a(t) = \left[ \frac{E^* D_a t}{L^2} - \frac{1}{6} - \frac{2}{\pi^2} \sum_{n=1}^{\infty} \left( \frac{\cos(n\pi)}{n^2} * \exp\left( \frac{-E^* D_a n^2 \pi^2 t}{L^2} \right) \right) \right] * C_b * L * A * \varepsilon
$$
 (2.17)

At very large time values, the exponential term in this equation quickly decays. Thus, at large time values, this equation may be approximated as a linear equation. Rearranging the above equation, the large time approximation becomes:

$$
Q_a(t) = \frac{C_b A \varepsilon E D_a t}{L} - \frac{C_b L A \varepsilon}{6}
$$
 (2.18)

By studying this linear equation, it is clear that when  $Q_a$  is plotted as a function of  $t$ , the y-axis intercept equals  $-C_b L A \varepsilon/6$ . Additionally, the line has a slope of  $C_b A \varepsilon E D_a / L$ .

The diffusion in the lipid layer may be represented as the change in total quantity of drug transported through the lipid layer over time as well. When Equation 2.14 is normalized by the area of the lipid layer, the resulting expression is the flux  $J_l(t)$  in units of mass per area per volume:

$$
J_l(t) = -D_l \left(\frac{\partial C_l}{\partial z}\right) \tag{2.19}
$$

To solve this partial differential equation for the lipid layer, a Laplace transform is used, hence obtaining:

$$
C_{l} = I^{-1} \left\{ \frac{C_{b}P\alpha\left(sP\cos\left((L-z)\sqrt{\frac{s}{D_{l}}}\right) + k_{D}\sqrt{\frac{s}{D_{l}}}\sin\left((L-z)\sqrt{\frac{s}{D_{l}}}\right)\right)}{s\left(sP\cos\left((L)\sqrt{\frac{s}{D_{l}}}\right) + k_{D}\sqrt{\frac{s}{D_{l}}}\sin\left((L)\sqrt{\frac{s}{D_{l}}}\right)\right)} \right\}
$$
(2.20)

When this equation is changed from the Laplace domain to the *z* domain, and the limit is taken for large *t* values, the following result is obtained:

$$
\lim_{t \to \infty} [C_l(z, t)] = \frac{C_b P \alpha [k_D(L - z) + PD_l]}{k_D L + PD_l}
$$
\n(2.21)

Taking the partial derivative of this equation with respect to z, the following is obtained:

$$
\frac{\partial C_l}{\partial z} = \frac{-C_b P \alpha k_d}{k_p L + PD_l} \tag{2.22}
$$

Flux through the lipid layer at the stratum corneum-viable epidermis interface,  $z = L$ , can be represented as:

$$
J_{l} = -D_{l} \frac{\partial C_{l}}{\partial z}\Big|_{z=L}
$$
 (2.23)

Substituting Equation 2.22 into Equation 2.23:

$$
J_l = \frac{D_l C_b k_p P \alpha}{k_p L + P D_l} \tag{2.24}
$$

When each term in the numerator and denominator of Equation 2.24 is divided by  $D_lP$ , the result is Equation 2.2, the steady state value obtained by Kontturi and Murtomäki (1996).

#### **CHAPTER 3**

#### **MODEL FOR A THREE-LAYER, TWO-PATHWAY SYSTEM**

The two-pathway model presented in Chapter 2 is suitable for modeling iontophoretic drug delivery through the stratum corneum. In other transdermal drug delivery systems, it may be desirable to model drug flux through not only the stratum corneum, but through the viable epidermis and the delivery vehicle itself as well.

While the model presented in Chapter 2 is suitable for characterizing transdermal delivery of a drug dissolved in a well-mixed solution, it is not suitable for situations in which the drug formulation or vehicle is intended to control the rate of delivery. Many examples of these types of systems exist, such as the contraceptive patch (Ortho Evra®, Ortho-McNeil Pharmaceuticals, Raritan, New Jersey), which utilizes a matrix system to control hormone delivery to the body (Burkman, 2004).

In this chapter, the two-pathway system is extended from a one-layer model encompassing only the stratum corneum to a three-layer model that encompasses the drug vehicle, the stratum corneum, and the viable epidermis as well. Work from Chapter 2 is further developed by incorporating not only mass transfer across the layer, but also between the aqueous and lipid pathways. Mass transfer between pathways has been addressed in previous developed partial differential equations (Lee et al., 1996), but a simultaneous analysis of both multiple pathways and multiple layers has not yet been performed.

#### **3.1 Partial Differential Equations for the Three-Layer Model**

The three layers represented by the model are the drug delivery vehicle, the stratum corneum, and the viable epidermis. The partial differential equations characterizing the drug delivery follow the same principles of Fickian diffusion as those applied to the twopathway, iontophoretic model. For the three-layer model, several assumptions are made. Firstly, it is assumed that the aqueous and lipid pathways exist in the stratum corneum and viable epidermis layers. The one-layer, two-pathway model for the stratum corneum has been previously discussed in Chapter 2. For the three-layer model, the viable epidermis is considered as a continuation of these two pathways, although drug delivery through the viable epidermis is expected to differ greatly from the stratum corneum, since the viable epidermis is more aqueous than the stratum corneum. The drug delivery vehicle is homogeneous in content, and thus, is treated as a one-pathway region.

The three regions (i.e. vehicle, stratum corneum, and viable epidermis) are represented as I, II, and III, respectively. The diffusion length through each region is taken to be  $L_i$ ,  $L_{ij}$ , and  $L_{ij}$ , respectively. See Figure 3.1.



Figure 3.1 Diagram of drug delivery through the vehicle, stratum corneum, and viable epidermis as characterized by the three-layer model. The darker regions in the stratum corneum and viable epidermis represent the lipid pathway; the lighter regions represent the aqueous pathway.

#### **3.1.1 Characterization of Transport Through the Drug Vehicle**

The equation for flow of the drug through the vehicle is:

$$
\frac{\partial C_I}{\partial t} = D_I \frac{\partial^2 C_I}{\partial z^2} \tag{3.1}
$$

The initial condition for this equation assumes uniform drug concentration  $C_{10}$ throughout the entire volume of the device at time 0. This is represented as:

$$
C_1(z, t = 0) = C_{I_0}
$$
\n(3.2)

Furthermore, there are two boundary conditions for Equation 3.1, one to indicate continuity of flux at the vehicle-stratum corneum interface, and one to indicate no flux exists at the edge of the vehicle furthest from the skin (i.e. at  $z = 0$ ). Symbolically, these conditions are represented as:

$$
D_{I} \frac{\partial C_{I}}{\partial z}(L_{I}, t) = D_{II, A} \frac{\partial C_{II, A}}{\partial z}(L_{I}, t)
$$
(3.3)

$$
D_{I} \frac{\partial C_{I}}{\partial z} (L_{I}, t) = D_{II, L} \frac{\partial C_{II, L}}{\partial z} (L_{I}, t)
$$
 (3.4)

$$
\frac{\partial C_I}{\partial z}(0,t) = 0\tag{3.5}
$$

In these equations, subscripts  $A$  and  $L$  designate the aqueous and lipid pathways, respectively.

#### **3.1.2 Characterization of Transport Through the Stratum Corneum**

Since the model assumes both lipid and aqueous pathways are available for drug delivery through the stratum corneum (Region II), separate equations and boundary conditions are written for each pathway.

For the aqueous pathway, the drug concentration profile in the stratum corneum over time is dependent upon three mass transfer mechanisms: 1) Fickian diffusion through the aqueous layer, 2) transfer from the lipid layer of the stratum corneum to the aqueous layer of the stratum corneum, and 3) transfer from the aqueous layer of the stratum corneum to the lipid layer of the stratum corneum. Diffusion is dependent upon the diffusion coefficient  $D_{H,A}$  and  $D_{H,L}$  for the drug in each pathway. The mass transfer between pathways depends on the concentration in each of the paths and a mass transfer coefficient. This model is represented as:

$$
\frac{\partial C_{H,A}}{\partial t} = D_{H,A} \frac{\partial^2 C_{H,A}}{\partial z^2} + k_{H,A} C_{H,L} - k_{H,L} C_{H,A}
$$
(3.6)

$$
\frac{\partial C_{H,L}}{\partial t} = D_{H,L} \frac{\partial^2 C_{H,L}}{\partial z^2} + k_{H,L} C_{H,A} - k_{H,A} C_{H,L}
$$
(3.7)

The coefficient for mass transfer to the aqueous layer from the lipid layer is  $k_{\mu}$ , and the coefficient for mass transfer to the lipid layer from the aqueous layer is  $k_{H,A}$ .

The initial conditions for these partial differential equations establish that at time 0, no drug is present in any part of the stratum corneum. Thus:

$$
C_{H,A}(z,t=0) = 0 \tag{3.8}
$$

$$
C_{H,L}(z,t=0) = 0 \tag{3.9}
$$

The stratum corneum boundary conditions establish that at the device-stratum corneum interface  $(z = L<sub>1</sub>)$ , the concentration in the stratum corneum equals the concentration in the device multiplied by the device/stratum corneum layer partition coefficient ( $P_{H,A}$  and  $P_{H,L}$  for the aqueous and lipid pathways, respectively).

$$
C_{H,A}(L_I, t > 0) = P_{H,A}C_I(L_I, t > 0)
$$
\n(3.10)

$$
C_{\Pi,L}(L_I, t > 0) = P_{\Pi,L}C_I(L_I, t > 0)
$$
\n(3.11)

Furthermore, at the opposite end of the stratum corneum  $(z = L_1 + L_1)$ , the flux continuity condition gives us the following relation between the stratum corneum and the viable epidermis:

$$
D_{II,A} \frac{\partial C_{II,A}}{\partial z} (L_I + L_{II}, t) = D_{III,A} \frac{\partial C_{III,A}}{\partial z} (L_I + L_{II}, t)
$$
(3.12)

$$
D_{II,L} \frac{\partial C_{II,L}}{\partial z} (L_I + L_{II}, t) = D_{III,L} \frac{\partial C_{III,L}}{\partial z} (L_I + L_{II}, t)
$$
(3.13)

#### **3.1.3 Characterization of Transport Through the Viable Epidermis**

Transport through the viable epidermis (Region III) may also be modeled as drug delivery through a set of two parallel pathways, one aqueous and the other lipid. As in the stratum corneum, mass transfer is modeled as the result of Fickian diffusion, transport from the aqueous to the lipid pathway, and transport from the lipid pathway to the aqueous pathway.
$$
\frac{\partial C_{III,A}}{\partial t} = D_{III,A} \frac{\partial^2 C_{III,A}}{\partial z^2} + k_{III,A} C_{III,L} - k_{III,L} C_{III,A}
$$
(3.14)

$$
\frac{\partial C_{III,L}}{\partial t} = D_{III,L} \frac{\partial^2 C_{III,L}}{\partial z^2} + k_{III,L} C_{III,A} - k_{III,A} C_{III,L}
$$
(3.15)

The initial condition of zero drug concentration at time 0 is also true for the viable epidermis.

$$
C_{III,A}(z,t=0) = 0 \tag{3.16}
$$

$$
C_{III,L}(z,t=0) = 0 \tag{3.17}
$$

The left boundary conditions (at  $z = L_I + L_I$ ) for the viable epidermis state that concentration in each of the pathways is a function of concentration in the stratum corneum at the same point and the stratum corneum-viable epidermis partition coefficients ( $P_{III,A}$  and  $P_{III,L}$  for the aqueous and lipid pathways, respectively). The right boundary conditions for the viable epidermis layer, which are representative of the point of drug transfer to the capillaries, assume infinite sink conditions. These boundary conditions are defined as:

$$
C_{III,A}(z = L_I + L_{II}, t > 0) = P_{III,A}C_{II}(z = L_I + L_{II}, t > 0)
$$
\n(3.18)

$$
C_{III,L}(z = L_I + L_{II}, t > 0) = P_{III,L} C_{II,L}(z = L_I + L_{II}, t > 0)
$$
\n(3.19)

$$
C_{III,A}(z = L_I + L_{II} + L_{III}, t > 0) = 0
$$
\n(3.20)

$$
C_{III,L}(z = L_I + L_{II} + L_{III}, t > 0) = 0
$$
\n(3.21)

# **3.2 Potential Applications of the Three-Layer Model**

The three-layer model for drug delivery through the skin is considerably more complex than the one-layer model presented in Chapter 2. The partial differential equations for the three-layer model would require additional attention in order to derive the analytical equation. However, even in differential form, understanding the partial differential equations themselves can be useful in understanding transdermal delivery data and how certain variables will effect specific outcomes.

The three-layer model highlights the fact that a given drug substance, when applied to the skin, must be transported through three layers, each of which have very different characteristics. The rate-limiting mass transfer step for this three-layer system must be identified. Any attempt to speed or control the overall rate of drug delivery to the systemic circulation must include careful consideration of this rate-determining step.

Typically, the stratum corneum, by nature of its crystalline lipid structure, is the rate-limiting step for drug diffusion. This factor serves as justification for including only the stratum corneum layer in the model discussed in Chapter 2. However, for some transdermal systems, situations demanding exceptionally slow drug release are possible. In such situations, the diffusion coefficient for the drug through the drug vehicle  $(D<sub>i</sub>)$ could be a critical parameter in ultimately controlling the rate of delivery to the systemic circulation.

Thus, even without solving the three-layer model partial differential equations, analyzing the diffusion coefficients relative to one another can provide insight into the transdermal delivery process. Such insight can then be utilized when designing experiments. For example, a study may need to quantify drug delivery through a series of differing drug vehicle formulations. Each formulation may contain varied concentrations of chemical enhancers, designed to speed the delivery process. Often, the time and resources required to test each modified formulation individually may be prohibitive. Analysis of the partial differential equation coefficients, however, can help

to narrow the number of potential formulations. For example, as discussed in Chapter 1, various chemical enhancers have been studied as a means of improving transdermal drug delivery. Analysis of the diffusion coefficients and partition coefficients can benefit such investigations by reducing the overall number of experiments run. If the diffusion and partition coefficient for a particular control group are known, then knowledge of the chemical properties of the skin and the drug substance may be used to plan and rationalize further trials. For instance, if partitioning of the drug into the skin is shown to be the rate-limiting step, then further studies can be designed to augment the partition coefficient rather than the diffusion coefficient.

As another example, assume that the diffusion,  $D_{II}$ , for a particular drug through the stratum corneum is known. Rather than testing each formulation for total effective diffusion through the skin, a small number of individual formulations could be tested to determine a set of baseline diffusions,  $\{D^*\}$ . Diffusion coefficients from this set can then be compared against one another and against  $D_{II}$ . This comparison would indicate if any significant differences in diffusion exist among the tested formulations, and if so, which candidate or candidates produce the most desirable results. Based on these preliminary results, an additional set of formulations could be prepared to optimize the formulation. Further comparison of diffusion coefficients could be performed among the subsequent set to further optimize, if necessary. The overall result from this approach would be determination of the desired drug vehicle formulation in a reduced number of empirical trials.

## **CHAPTER 4**

# **DATA ANALYSlS USlNG THE TWO-PATHWAY MODEL**

Thus far, two separate mathematical models have been presented as means of characterizing transdermal drug delivery phenomena. This section applies the transient model discussed in Chapter 2 to the analysis of *in vitro* transdermal drug delivery data. A simplification of this model is presented. The application of non-linear regression software for data analysis is then explained. Finally, the results of the analysis are discussed.

# **4.1 Analysis of Transdermal lontophoretic Data for Three Drug Substances**

A series of Franz diffusion cell experiments were conducted by Wang (2004) to study iontophoretic delivery of tricyclic antidepressants through human skin. The three drugs studied were amitriptyline HC1, clomipramine HC1, and nortriptyline HC1. Each of these molecules consists of three cyclical hydrocarbon chains and a subgroup chain extending from the center ring. The structure of the center ring and the subgroup chain differ slightly; this difference contributes to slight differences in molecular mass among the three drugs.

Wang's investigations consisted of varying the donor cell drug concentration (0.0032 M, 0.016 M, and 0.032 M) and varying the applied iontophoretic current density  $(0.1 \text{ mA/cm}^2$ , 0.2 mA/cm<sup>2</sup>, 0.3 mA/cm<sup>2</sup>, and 0.4 mA/cm<sup>2</sup>). For each specific set of the variables (that is, drug molecule, drug concentration, and current density), three individual determinations were performed. All three determinations for a given set of

**26**

concentration and current conditions were performed on human skin samples from the same donor. The large quantity of samples required for the study prohibited the use of the same donor for all studied conditions.

Human skin samples were placed in a Franz diffusion cell apparatus. The exposed surface area of each sample was  $0.64 \text{ cm}^2$  and the skin thickness of each sample was  $500±100 \mu m$ . At start up, each donor cell contained the drug substance dissolved in water to the desired molar concentration. Each receptor cell contained a phosphate saline solution. Analysis of the quantity of active in the receptor cell was performed by extracting samples from the receptor solution every hour for a total of 8 hours. Samples were analyzed for drug content via HPLC. Further details regarding the methods are given in Wang, 2004.

# **4.2 Simplification of the Two-Pathway Model**

In Chapter 2, a two-pathway system describing transient drug transport through the stratum corneum was presented. These transient equations were based on the steady state equations developed by Kontturi and Murtomäki (1996).

One of the important assumptions of the Kontturi-Murtomäki model is that ionized drug molecules can only travel through the aqueous pathway of the stratum corneum. This assumption has an important impact on the analysis of the data set described in Section 4.1. All three selected drugs were salts, and thus, were highly soluble in the aqueous delivery vehicle. Having high solubilities, the quantity of nonionized drug is essentially zero. Since the lipid pathway, as defined by Kontturi-Murtomaki, supports mass transfer of non-ionized drug only, the lipid pathway characterized by this model cannot contribute to the flux of salts through the stratum corneum. Therefore, the analysis herein is performed using the aqueous pathway equation only.

Equation 2.17 established a transient model for iontophoretic drug delivery through the aqueous pathway of the stratum corneum. For the given system, however, several simplifications to this equation can be made.

In Equation 2.17, iontophoresis was shown to impact transdermal drug delivery through the enhancement factor *E ,* which serves as a multiplier for the diffusion term  $D_a$ . To perform data analysis, the diffusion coefficient  $D_a$  and the enhancement factor *E* may be treated as a single, combined variable, defined here as *D' .*

The drug concentration in the aqueous pathway at the skin-reservoir interface can be considered as a function of the bulk drug concentration and a partition coefficient *P .* As such, the drug concentration within the skin at the interface is represented as  $PC<sub>b</sub>$ . However, for the purpose of nonlinear regression modeling, this quantity may be treated as a combined variable, annotated here as *C'.*

Additionally, Equation 2.17 contained a term  $\varepsilon$  which represented the surface area fraction belonging to the aqueous pathways. Although Konttun and Murtomäki use a quantity of  $10^{-4}$  for this parameter (1996), an exact value is not known for the analyzed system. This parameter must be included if separate fluxes through both the aqueous and lipid pathways are to be derived. However, because only aqueous pathway diffusion is assumed, the parameter  $\varepsilon$  can be eliminated. The cumulative amount of drug through the lipid pathway is assumed to be  $0$  for all time points. Thus, the cumulative amount of drug through a skin sample of surface area *A* is equal to the cumulative amount of drug through the aqueous pathway surface area  $A \varepsilon$ . For analysis, therefore, the cumulative amount of drug,  $Q_a(t)$ , may be normalized by the total surface area *A*. The resulting quantity, defined as  $M(t)$ , is expressed in units of mass per surface area.

The analytical solution to the aqueous layer equation includes an exponential term embedded in an infinite summation series. Since the exponential portion of this series causes the summation to decay quickly, the summation may be truncated after only a few terms. For the analysis discussed herein, three terms (i.e.  $n = 3$ ) were used.

Incorporating these simplifications, Equation 2.17 can be re-written as:

$$
M(t) = \left[ \frac{D't}{L^2} - \frac{1}{6} - \frac{2}{\pi^2} \sum_{n=1}^3 \left( \frac{\cos(n\pi)}{n^2} * \exp\left( \frac{-D'n^2 \pi^2 t}{L^2} \right) \right) \right] * C' * L \tag{4.1}
$$

As previously described in Chapter 2, *L* is the length of the diffusion pathway and is considered to be equal to the thickness of the skin samples  $(500 \text{ µm})$ .

# **4.3 Method of Data Analysis**

For each Franz cell determination, the cumulative quantity of drug in the receptor cell was measured after every hour for a total of eight hours (Wang, 2004). To find the set of  $M(t)$  values for a given set of conditions, the individual  $M(t)$  values for each of the three determinations were averaged to find the mean quantity  $\overline{M}$  at each hour.

For data analysis, NLREG nonlinear regression analysis software (Author: Phillip Sherrod, www.nlreg.com) was used on a Dell personal computer to provide a set of numerical solutions to Equation 4.1. The set of  $\overline{M}$  values were entered into NLREG for each drug at each specified set of conditions. The software regressed the data and returned values for *D'* and *C'* for each set of data.

# **4.4 Resulting Diffusion and Partition Coefficients**

After performing the nonlinear regression analysis, the data sets were analyzed to determine the existence of any correlation between either *D'* or *G'* and current density and/or donor cell drug concentration. Analysis was performed using analysis of variance (ANOVA) for each of the three drugs.

# **4.4.1 Relationship of Current Density to Drug Diffusion Coefficients**

For each of the three drugs, results of ANOVA showed no statistically significant relationship between the current density and the diffusion coefficient *D'.* This result indicated that the diffusion coefficient is constant for a particular drug irrespective of iontophoretic current. The mean diffusion coefficient and standard deviation for each drug are given in Table 4.1.

Table 4.1 Molar Mass and Calculated Diffusion Coefficients for Amitriptyline HCl, Clomipramine HCl, and Nortriptyline HCl

Drug	<b>Molar Mass</b> [g/mol]	<b>Diffusion</b> Coefficient $(*10-4)$ $[\text{cm}^2/\text{hr}]$	
Amitriptyline	313.9	$1.78 \pm 0.33$	
Clomipramine	351.3	$1.68 \pm 0.46$	
Nortriptyline	299.8	$1.05 \pm 0.14$	

As presented in Equation 2.17, Kontturi and Murtomäki (1996) incorporated the effect of iontophoresis into their mathematical model through the use of the enhancement factor *E .* The magnitude of *E* was taken to increase with current density. The results of the ANOVA analysis conducted herein are contrary to the findings of Kontturi and Murtomaki. As previously discussed, the diffusion coefficient and the enhancement

factor *E* were treated as the lumped parameter *D'*. Based on Equation 2.17, a relationship between *D'* and applied current would be expected. However, the constant value of *D'* indicates that diffusivity is not dependent upon current for the drug substances studies at the range of currents studied.

# **4.4.2 ANOVA Analysis of Drug Partition Coefficients**

Nonlinear analysis of Equation 4.1 included the parameter *C',* which represents the concentration within the stratum corneum at the donor cell reservoir-skin interface (i.e.  $z=0$ ). *C'* is expressed in units of  $\mu g/cm^3$ . The concentration at this point is a function of both the bulk drug concentration in the applied delivery device  $(C_b)$  and the drug partition coefficient  $P$ . In Section 4.2, the value of  $C'$  is taken to be the product of these two. Two ANOVA analyses were carned out. First, the values of *C'* were analyzed for any correlation to iontophoretic current or to applied bulk concentration. Then, the same analysis was conducted after normalizing C' by the known bulk concentration  $C_b$ . The results of the ANOVA analysis are given in Table 4.2.

Drug	<b>Correlation to</b> <b>Iontophoretic Current</b>			<b>Correlation to the Bulk</b> <b>Concentration in the Vehicle</b>		
	$\mathbf{F}_{\text{critical}}$ Value	<b>Test</b> <b>Statistic</b> from Analysis of €'	<b>Test</b> <b>Statistic</b> from <b>Analysis of</b>	$\mathbf{F}_{\text{critical}}$ Value	<b>Test</b> <b>Statistic</b> from <b>Analysis of</b> C'	<b>Test</b> <b>Statistic</b> from <b>Analysis of</b>
Amitriptyline	6.94	16.13	2.68	6.94	5.57	55.75
Clomipramine	5.14	14.06	4.90	4.76	6.41	57.02
Nortriptyline	5.14	6.80	2.66	4.76	0.77	28.86

**Table 4.2** Results of ANOVA Analysis for the Skin Concentration C' and the Drug **Partition Coefficient P** 

The ANOVA results showed that a statistically significant relationship exists between iontophoretic current and the skin-side concentration  $C'$ . However, when the partition coefficient is calculated by normalizing  $C'$  for the bulk drug concentration within the vehicle, ANOVA analysis showed no statistically significant correlation between applied current the partition coefficient.

Analysis of a possible correlation to bulk concentration gave the opposite result. With the exception of clomipramine, no statistically significant relationship was noted between the skin-side concentration  $C'$  and the bulk concentration  $C<sub>b</sub>$ . After normalizing *C'* by  $C<sub>b</sub>$  to obtain *P'*, a strong correlation was detected for all three drugs, as expected.

The positive correlation between the magnitude of applied iontophoretic current and the stratum corneum concentration at  $z = 0$  indicates that iontophoresis enhances flux through the stratum corneum by increasing the concentration of drug penetrating the skin at the skin-device interface. However, the lack of correlation between *P'* and applied current indicate that the mechanism for enhancement is not simply increasing the drug's partition coefficient.

The permeation from the bulk solution in the drug reservoir to the skin is greatly enhanced at lower concentrations. This trend was generally observed for all three of the drugs and indicates that as concentration increases, a lesser fraction of the drug in the donor cell is transmitted through the skin. This effect is shown in Figure 4.1

The results of the analysis indicate that other factors may be impacting upon the magnitude of stratum corneum concentration at the interface. One such factor that could impact upon *C'* is the skin damage factor. The skin damage factor may change the available volume in which the drug concentrates within the skin.



Figure 4.1 Values of P for (a) amitriptyline HCl, (b) clomipramine HCl, and (c) nortriptyline HCl. Concentrations are in units of mol/L. Among trials run at equal current densities, P, calculated as the ratio of C'/C<sub>bulk</sub>, decreased with increasing concentration.

# **4.5 Comparison of Flux from Nonlinear Regression and Graphical Analysis**

Wang (2004) employed a graphical method for computing the flux. The cumulative amount through the skin versus time was plotted for each data set. The graph yielded a curve function that could be approximated as a linear function at large time values. From the linear region of the graph, the slope was determined and then normalized by the skin sample surface area in order to calculate the empirical flux.

As a means of assessing the results of the transient state equation versus the flux calculated by the conventional, graphical method, a parity plot (Figure 4.2) was constructed. The empirical flux values  $J_g$  derived from graphing the data (Wang, 2004), was compared to the theoretical flux values  $J_t$  computed from the transient state equation coefficients.

To calculate theoretical flux values  $J_t$ , the transient state equation and large time approximation were used. At large *t* values, Equation 2.17 becomes linear. The slope of this equation is equal to the product of the diffusion coefficient and the concentration at the skin-device boundary divided by the diffusion pathway length. Thus, the flux as computed by the transient equation parameters  $(J_t)$ , with units of mass per time area, can be calculated as

$$
J_t = \frac{C^* D'}{L} \tag{4.2}
$$

For the given data sets, the exposed surface area in the Franz cell diffusion apparatus was  $0.64 \text{ cm}^2$ . The length of the diffusion pathway was considered equal to the thickness of the skin sample (i.e.  $500\pm100$   $\mu$ m). Tortuosity of the path was considered negligible with respect to the entire thickness of the skin. A comparison of the flux

values calculated from the nonlinear regression parameters and applied iontophoretic current is shown in Figure 4.3.

The two sets of flux values  $J_g$  and  $J_t$  were in close agreement with each other. By plotting these two fluxes against one another and performing a linear fit, a regression parameter of 0.97 and a slope of nearly unity (0.97) were obtained. This result indicates that the two methods are in close agreement with each other.



Figure 4.2 Comparison of flux values obtained from the graphical interpretation of empirical data  $(J_g)$  and from theoretical calculation using the derived nonlinear regression parameters  $(J_t)$ .



**Figure 4.3** Flux values  $J_t$  calculated for (a) amitriptyline HCl, (b) clomipramine HCl, and (c) nortriptyline HCl. Concentrations are in units of mol/L. For the control group (i.e. no applied current), data for only one concentration (0.032 M) was available. For amitriptyline HCl, data for 0.1 mA/cm<sup>2</sup> was not available.

Flux determination using the conventional, graphical method is advantageous for several reasons. This method can be quickly and easily applied to Franz cell analysis. For characterizing iontophoretic data, the graphical approach is useful because flux through the skin dunng iontophoresis quickly becomes constant. Thus, the large time value approximation required by the graphical method can be applied relatively soon after drug device application. For example, most of the data points for the drugs analyzed herein fell within the linear range after the first hour. This minimized the number of data points omitted from the regression analysis. Among the disadvantages of the graphical method are: 1) the analysis does not capture the entire data set, 2) the selection of points in the linear portion of the curve can be subjective in nature, and 3) differing answers may be obtained based on the inclusion or omission of data points.

Use of the transient equation for delivery across the viable epidermis eliminates these concerns since all data points may be used. A more complete charactenzation of the data, even at small time values prior to reaching steady flux, may be achieved.

Historically, the major disadvantage of using a transient equation such as Equation 4.1 has been that it is nonlinear, and therefore, difficult to regress. However, by implementing nonlinear regression software, data sets can be very easily fit to an equation such as this.

More importantly, use of the transient equation to solve for flux enables one to determine the diffusion coefficient and to characterize the concentration within the stratum corneum at the skin-device interface. Such information can then be used to enhance the understanding of how a particular set of variables works to promote or hinder delivery through the skin.

# **4.6 Effect of** *D'* **and** *G'* **Parameters on Flux Through the Stratum Corneum**

Typically, the key parameter of interest in transdermal drug delivery studies is flux. Since delivery through the stratum corneum is usually a rate-limiting step in the overall delivery of drug to the blood stream, control of this parameter, and understanding the options for enhancing it, are of great interest.

As the data shows, the calculated diffusion coefficients differed among drug substances but did not vary substantially with changes in current density or bulk concentration. As evidence of this, nortriptyline HC1 produced the highest overall flux values, but the smallest diffusion coefficient of the three drugs analyzed.

# **CHAPTER 5**

# **CONCLUSlONS**

The close agreement between the flux values derived from the aqueous layer transient state equation and the graphical method demonstrate the suitability of the theoretical model for iontophoretic delivery. Additionally, the results act as further validation of the conventional, graphical method. The graphical method may be preferred as a suitable, simple means of flux analysis.

The transient model equations show that the delivery of amitriptyline HC1, clomipramine HC1, and nortriptyline HC1 is dependent upon the diffusion coefficient parameter and the bulk drug concentration. The large time approximation for the accumulated drug penetration is helpful in understanding this effect. The large time approximation mathematically describes how these parameters impact overall drug delivery.

A major challenge in the designing of drugs for transdermal delivery is the establishment of an adequate and steady rate of delivery through the skin. The implications of the large time approximation equation can be readily applied in developing the correct system for the correct delivery strategy.

The large time approximation shows that drug delivery can be influenced by bulk concentration, the drug partition coefficient, the diffusion coefficient, and the diffusion pathway length. Bulk concentration is frequently the easiest of these to control, from a formulation standpoint. It is also a very important parameter because it impacts both the rate of drug transport and the overall quantity of drug transported.

**39**

Increasing the value of the diffusion coefficient will also increase drug delivery through the skin. Diffusivity is related to chemical or physical properties of the skin, the drug and the vehicle into which the drug is formulated. In order to utilize knowledge of the diffusion coefficient to augment overall drug permeation, an understanding of which factors increase diffusivity is required.

Typically for a biological system such as the skin, the diffusion pathway length is modeled as a constant of the skin itself. Many studies available in the literature, however, indicate that tortuosity of the stratum corneum can vary with hydration levels. Since the diffusion pathway is a lumped parameter that incorporates both membrane thickness and path tortuosity, empirical results suggest means of altering the diffusion pathway length do exist (Talereja et al., 2001). Furthermore, Tezel and Mitragotri note (2003) that the size of the diffused particles may change the effective tortuosity. The skin contains pores that extend both perpendicular to and parallel to the direction of drug transport. Due to their size, smaller particles may be able to diffuse through a greater number of paths, while large particles are more limited in the number of diffusion pathways through which they can pass. As such, diffusion of the smaller particles through the stratum corneum may follow a less direct path than diffusion of larger particles. This factor may be the reason why nortriptyline HC1, which had the smallest molar mass, also had the smallest diffusion coefficient.

A series of partial differential equations for a three-layer system were additionally presented. Studying the coefficients in this equation can also help to illuminate the mechanisms for drug delivery through this type of system.

In the development of drug delivery regimens, particularly those used for high potency drugs, it may be necessary to understand the delivery dynamics at the initial time points as well as after achieving steady flux. Additionally, particularly for the purposes of data collection and analysis, one may wish to know after what time point is the large time approximation appropriate. By using nonlinear regression, the dilemma of judging which data to include and which data to omit is circumvented. Furthermore, the nonlinear regression method allows one to calculate coefficients such as the diffusion coefficient and the partition coefficient. Utilizing this information, additional insight into the mechanisms of transdermal drug delivery can be achieved.

## **APPENDIX**

# **NLREG PROGRAM RESULTS**

This Appendix contains the results generated from nonlinear analysis with NLREG.

### Amitriptyline 0.5%, 0.2 mA/cm^2

1: Title "Aqueous layer equation"; 2: Variable time; // Cooling time in hr 3: Variable Clime;<br>3: Variable Qa; // Quantity thru skin in micrograms<br>4: Constant L=500\*10^-4; // Skin thickness in cm<br>5: Parameter Da; // Diffusion coefficient in aqueous layer<br>6: Parameter C1; // Bulk concentration 7: Function Qa= C1\*L\* (Da\*time/L^2-1/6-2/pi^2\* (cos (pi) \*exp (-Da\*pi^2\*time/L^2)+cos(pi\*2)/4\*exp(-Da\*4\*pi^2\*time/L^2)+cos(pi\*3)/9\*exp(- $Da*9*pi^2*time/L^2))$ ; 8: Plot xlabel="Time (hr)", ylabel="Drug permeated (micrograms)"; 9: Data; Beginning computation... Stopped due to: Relative function convergence. ---- Final Results ----NLREG version 6.1 Copyright (c) 1992-2004 Phillip H. Sherrod. Aqueous layer equation Number of observations =  $9$ Maximum allowed number of iterations =  $500$ Convergence tolerance factor =  $1.000000E-010$ Stopped due to: Relative function convergence. Number of iterations performed = 262 Final sum of squared deviations =  $1.7888542E+002$ Final sum of deviations =  $4.8031824E+000$ Standard error of estimate =  $5.0552$ Average deviation =  $3.8251$ Maximum deviation for any observation =  $7.77709$ Proportion of variance explained  $(R^2) = 0.9985$  (99.85%) Adjusted coefficient of multiple determination  $(Ra^2) = 0.9983$  (99.83%) Durbin-Watson test for autocorrelation = 1.593 Warning: Covariance matrix could not be computed because the finite-difference Hessian was indefinite. Analysis completed 14-Mar-2004 16:36. Runtime = 0.06 seconds. ---- Descriptive Statistics for Variables ----Variable Minimum value Maximum value Mean value Standard dev. --------------------time 0<br>
Qa 0 334.5104 132.3387 120.9255 ---- Calculated Parameter Values ----Parameter Initial guess Final estimate 

15115.8932

Da 1 0.000188528046<br>C1 1 15115.8932

Da

---- Analysis of Variance ----



#### Amitriptyline 0.1%, 0.2 mA/cm^2

1: Title "Aqueous layer equation"; 2: Variable time; // Cooling time in hr 3: Variable Qa; // Quantity thru skin in micrograms 4: Constant  $L=500*10^{\circ} - 4$ ;  $//$  Skin thickness in cm // Diffusion coefficient in aqueous layer 5: Parameter Da; 6: Parameter C1; // Bulk concentration 7: Function Qa=  $Cl*L*(Da*time/L^2-1/6-2/pi^2*(\cos(pi)*exp(-$ Da\*pi^2\*time/L^2)+cos(pi\*2)/4\*exp(-Da\*4\*pi^2\*time/L^2)+cos(pi\*3)/9\*exp(- $Da*9*pi^2*time/L^2))$ ; 8: Plot xlabel="Time (hr)", ylabel="Drug permeated (micrograms)";  $9: Data;$ Beginning computation... Stopped due to: Relative function convergence. ---- Final Results ----NLREG version 6.1 Copyright (c) 1992-2004 Phillip H. Sherrod. Aqueous layer equation Number of observations = 9 Maximum allowed number of iterations = 500 Convergence tolerance factor =  $1.000000E-010$ Stopped due to: Relative function convergence. Number of iterations performed = 267 Final sum of squared deviations =  $2.6638562E+002$ Final sum of deviations =  $1.0011188E+001$ Standard error of estimate =  $6.16888$ Average deviation =  $3.70543$ Maximum deviation for any observation = 13.9705 Proportion of variance explained  $(R^2) = 0.9966$  (99.66%) Adjusted coefficient of multiple determination  $(Ra^2) = 0.9962$  (99.62%) Durbin-Watson test for autocorrelation =  $1.793$ 

Warning: Covariance matrix could not be computed because the finite-difference Hessian was indefinite. Analysis completed  $14$ -Mar-2004 16:40. Runtime = 0.05 seconds.

---- Descriptive Statistics for Variables ----



#### ---- Calculated Parameter Values ----



### Amitriptyline 1%, 0.2 mA/cm^2

1: Title "Aqueous layer equation"; 2: Variable time; // Cooling time in hr 3: Variable Qa; // Quantity thru skin in micrograms 4: Constant L=500\*10^-4;  $//$  Skin thickness in cm // Diffusion coefficient in aqueous layer 5: Parameter Da; 6: Parameter C1; // Bulk concentration 7: Function Qa= C1\*L\* (Da\*time/L^2-1/6-2/pi^2\* (cos (pi) \*exp (- $Da*pi^2*time/L^2) + cos(pi*2)/4*exp(-Da*4*pi^2*time/L^2) + cos(pi*3)/9*exp(-D2*exp(D2*12))$  $Da*9*pi^2*time/L^2))$ ; 8: Plot xlabel="Time (hr)", ylabel="Drug permeated (micrograms)";  $9: Data;$ Beginning computation... Error executing line 7: Function Qa= C1\*L\* (Da\*time/L^2-1/6-2/pi^2\* (cos (pi) \*exp(- $Da*pi^2*time/L$ Error: Argument to exp function is too large (1117.26) Error executing line 7: Function Qa= C1\*L\* (Da\*time/L^2-1/6-2/pi^2\* (cos (pi) \*exp(-Da\*pi^2\*time/L Error: Argument to exp function is too large (2513.84) Error executing line 7: Function Qa= C1\*L\* (Da\*time/L^2-1/6-2/pi^2\* (cos(pi)\*exp(-Da\*pi^2\*time/L Error: Argument to exp function is too large (1090.08) Error executing line 7: Function Qa= C1\*L\*(Da\*time/L^2-1/6-2/pi^2\*(cos(pi)\*exp(-Da\*pi^2\*time/L Error: Argument to exp function is too large (756.387) Stopped due to: Relative function convergence.  $---$  Final Results  $---$ NLREG version 6.1 Copyright (c) 1992-2004 Phillip H. Sherrod. Aqueous layer equation Number of observations = 9 Maximum allowed number of iterations = 500 Convergence tolerance factor =  $1.000000E-010$ Stopped due to: Relative function convergence. Number of iterations performed = 250 Final sum of squared deviations =  $1.3059280E+002$ Final sum of deviations =  $-2.3224444E-001$ Standard error of estimate = 4.31927 Average deviation =  $3.10056$ Maximum deviation for any observation =  $7.27618$ Proportion of variance explained  $(R^2) = 0.9987$  (99.87%) Adjusted coefficient of multiple determination  $(Ra^2) = 0.9985$  (99.85%) Durbin-Watson test for autocorrelation =  $1.818$ Warning: Covariance matrix could not be computed because the finite-difference Hessian was indefinite. Analysis completed 14-Mar-2004 16:46. Runtime = 0.11 seconds. ---- Descriptive Statistics for Variables ---- $U_2$   $V_1$   $V_2$ Minimum unlue Maximum unlue Moon unlue Ctandard dev







### Amitriptyline 0.5%, 0.3 mA/cm^2

1: Title "Aqueous layer equation"; 2: Variable time; // Cooling time in hr 3: Variable Qa; // Quantity thru skin in micrograms 4: Constant L=500\*10^-4;<br>5: Parameter Da; // Diffusion coefficient in aqueous layer 6: Parameter C1; // Bulk concentration 7: Function Qa= C1\*L\* (Da\*time/L^2-1/6-2/pi^2\* (cos (pi) \*exp (-Da\*pi^2\*time/L^2)+cos(pi\*2)/4\*exp(-Da\*4\*pi^2\*time/L^2)+cos(pi\*3)/9\*exp(- $Da*9*pi^2*time/L^2))$ ; 8: Plot xlabel="Time (hr)", ylabel="Drug permeated (micrograms)";  $9: Data:$ Beginning computation... Stopped due to: Relative function convergence. ---- Final Results ----NLREG version 6.1 Copyright (c) 1992-2004 Phillip H. Sherrod. Aqueous layer equation Number of observations =  $8$ Maximum allowed number of iterations = 500 Convergence tolerance factor =  $1.000000E-010$ Stopped due to: Relative function convergence. Number of iterations performed =  $259$ Final sum of squared deviations =  $1.1991658E+002$ Final sum of deviations =  $-5.5311663E+000$ Standard error of estimate =  $4.47058$ Average deviation =  $3.26535$ Maximum deviation for any observation =  $7.70795$ Proportion of variance explained  $(R^2) = 0.9992$  (99.92%) Adjusted coefficient of multiple determination  $(Ra^2) = 0.9990$  (99.90%) Durbin-Watson test for autocorrelation = 1.965

Warning: Covariance matrix could not be computed because the finite-difference Hessian was indefinite. Analysis completed  $14$ -Mar-2004 16:51. Runtime = 0.11 seconds.

---- Descriptive Statistics for Variables ----



---- Calculated Parameter Values ----





### Amitriptyline 0.1 %, 0.3 mA/cm^2

1: Title "Aqueous layer equation"; 2: Variable time; // Cooling time in hr 3: Variable Qa; // Quantity thru skin in micrograms 4: Constant L=500\*10^-4;  $//$  Skin thickness in cm // Diffusion coefficient in aqueous layer 5: Parameter Da; 6: Parameter C1; // Bulk concentration 7: Function Qa= Cl\*L\* (Da\*time/L^2-1/6-2/pi^2\* (cos (pi) \*exp (-Da\*pi^2\*time/L^2)+cos(pi\*2)/4\*exp(-Da\*4\*pi^2\*time/L^2)+cos(pi\*3)/9\*exp(- $Da*9*pi^2*time/L^2))$ ; 8: Plot xlabel="Time (hr)", ylabel="Drug permeated (micrograms)";  $9: Data;$ Beginning computation... Error executing line 7: Function Qa= C1\*L\* (Da\*time/L^2-1/6-2/pi^2\* (cos (pi) \*exp(- $Da * pi^2 * time/L$ Error: Argument to exp function is too large (848.706) Error executing line 7: Function Qa= C1\*L\* (Da\*time/L^2-1/6-2/pi^2\* (cos(pi)\*exp(- $Da * pi^2 * time/L$ Error: Argument to exp function is too large (1909.59) Error executing line 7: Function Qa= C1\*L\* (Da\*time/L^2-1/6-2/pi^2\* (cos (pi) \*exp(-Da\*pi^2\*time/L Error: Argument to exp function is too large (696.047) Error executing line 7: Function Qa= C1\*L\* (Da\*time/L^2-1/6-2/pi^2\* (cos (pi) \*exp(-Da\*pi^2\*time/L Error: Argument to exp function is too large (535.655) Stopped due to: Both parameter and relative function convergence. ---- Final Results ----NLREG version 6.1 Copyright (c) 1992-2004 Phillip H. Sherrod. Aqueous layer equation Number of observations =  $8$ Maximum allowed number of iterations =  $500$ Convergence tolerance factor =  $1.000000E-010$ Stopped due to: Both parameter and relative function convergence. Number of iterations performed =  $276$ Final sum of squared deviations =  $1.0768419E+002$ Final sum of deviations =  $-3.0535445E+000$ Standard error of estimate =  $4.23643$ Average deviation =  $3.27239$ Maximum deviation for any observation =  $6.84825$ Proportion of variance explained  $(R^2) = 0.9991$  (99.91%) Adjusted coefficient of multiple determination  $(Ra^2) = 0.9990$  (99.90%) Durbin-Watson test for autocorrelation = 1.969 Warning: Covariance matrix could not be computed because the finite-difference Hessian was indefinite. Analysis completed  $14$ -Mar-2004 16:59. Runtime = 0.06 seconds. ---- Descriptive Statistics for Variables ----Variable Minimum value Maximum value Standard dev. Mean value





#### Amitriptyline  $1\%$ , 0.3 mA/cm<sup> $\sim$ </sup>2 1: Title "Aqueous layer equation";

2: Variable time; // Cooling time in hr 3: Variable Qa; // Quantity thru skin in micrograms // Skin thickness in cm 4: Constant L=500\*10^-4; // Diffusion coefficient in aqueous layer 5: Parameter Da; 6: Parameter C1; // Bulk concentration 7: Function Qa= Cl\*L\* (Da\*time/L^2-1/6-2/pi^2\* (cos (pi)\*exp(- $\mathtt{Da} * \mathtt{pi}^2 * \mathtt{time}/\mathtt{L}^2) + \mathtt{cos}(\mathtt{pi} * 2) / 4 * \mathtt{exp}(-\mathtt{Da} * 4 * \mathtt{pi}^2 * \mathtt{time}/\mathtt{L}^2) + \mathtt{cos}(\mathtt{pi} * 3) / 9 * \mathtt{exp}(-\mathtt{m} * 2)$  $Da*9*pi^2*time/L^2))$ ; 8: Plot xlabel="Time (hr)", ylabel="Drug permeated (micrograms)";  $9: Data;$ Beginning computation... Stopped due to: Relative function convergence. ---- Final Results ----NLREG version 6.1 Copyright (c) 1992-2004 Phillip H. Sherrod. Aqueous layer equation Number of observations =  $8$ Maximum allowed number of iterations = 500 Convergence tolerance  $factor = 1.000000E-010$ Stopped due to: Relative function convergence. Number of iterations performed =  $254$ Final sum of squared deviations =  $1.3849388E+002$ Final sum of deviations =  $-7.8437033E+000$ Standard error of estimate =  $4.80441$ Average deviation =  $3.03441$ Maximum deviation for any observation =  $9.80597$ Proportion of variance explained  $(R^2) = 0.9990$  (99.90%) Adjusted coefficient of multiple determination  $(Ra^2) = 0.9988$  (99.88%) Durbin-Watson test for autocorrelation = 1.887

Warning: Covariance matrix could not be computed because the finite-difference Hessian was indefinite. Analysis completed 14-Mar-2004 17:04. Runtime = 0.06 seconds.

---- Descriptive Statistics for Variables ----



---- Calculated Parameter Values ----





### Amitriptyline 0.5%, 0.4 mA/cm^2 1: Title "Aqueous layer equation"; 2: Variable time; // Cooling time in hr

3: Variable Qa; // Quantity thru skin in micrograms 4: Constant  $\overline{L} = 500 \times 10^{-2} - 4$ ; // Skin thickness in cm<br>5: Parameter Da; // Diffusion coefficient in aqueous layer 4: Constant  $L =$ <br>5: Parameter Da; // Diffusion  $L =$ <br>5: Parameter C1; // Bulk concentration<br> $L^2 = \frac{L^2 - 1}{6 - 2}$ 7: Function Qa= C1\*L\* (Da\*time/L^2-1/6-2/pi^2\* (cos (pi)\*exp(-Da\*pi^2\*time/L^2)+cos(pi\*2)/4\*exp(-Da\*4\*pi^2\*time/L^2)+cos(pi\*3)/9\*exp(- $Da*9*pi^2*time/L^2))$ ; 8: Plot xlabel="Time (hr)", ylabel="Drug permeated (micrograms)";  $9: Data;$ Beginning computation... Stopped due to: Relative function convergence. ---- Final Results ----NLREG version 6.1 Copyright (c) 1992-2004 Phillip H. Sherrod. Aqueous layer equation Number of observations =  $8$ Maximum allowed number of iterations = 500 Convergence tolerance factor =  $1.000000E-010$ Stopped due to: Relative function convergence. Number of iterations performed =  $242$ Final sum of squared deviations =  $1.7078124E+002$ Final sum of deviations =  $-6.4273812E+000$ Standard error of estimate =  $5.33512$ Average deviation =  $3.69599$ Maximum deviation for any observation = 9.53796 Proportion of variance explained  $(R^2) = 0.9992$  (99.92%) Adjusted coefficient of multiple determination  $(Ra^2) = 0.9990$  (99.90%) Durbin-Watson test for autocorrelation = 2.140

Warning: Covariance matrix could not be computed because the finite-difference Hessian was indefinite. Analysis completed 14-Mar-2004 17:09. Runtime = 0.06 seconds.

---- Descriptive Statistics for Variables ----



---- Calculated Parameter Values ----





### Amitriptyline 0.1%, 0.4 mA/cm^2

1: Title "Aqueous layer equation"; 2: Variable time; // Cooling time in hr 3: Variable Qa; // Quantity thru skin in micrograms 4: Constant  $\overline{L} = 500 \times 10^{-2} - 4$ ; // Skin thickness in cm<br>5: Parameter Da; // Diffusion coefficient in aqueous layer 5: Parameter Da;  $\frac{1}{2}$  // Diffusion coeff<br>6: Parameter C1; // Bulk concentration 7: Function Qa=  $Cl^{\star}L^{\star}$  (Da\*time/L^2-1/6-2/pi^2\* (cos(pi)\*exp(- $Da*pi^22*time/L^2)+cos(p1*2)/4*exp(-Da*4*pi^2*time/L^2)+cos(p1*3)/9*exp(-D4*2)$  $Da*9*pi^2*time/L^2))$ ; 8: Plot xlabel="Time (hr)", ylabel="Drug permeated (micrograms)";  $9: Data;$ Beginning computation... Stopped due to: Relative function convergence. ---- Final Results ----NLREG version 6.1 Copyright (c) 1992-2004 Phillip H. Sherrod. Aqueous layer equation Number of observations =  $8$ Maximum allowed number of iterations = 500 Convergence tolerance factor =  $1.000000E-010$ Stopped due to: Relative function convergence. Number of iterations performed =  $240$ Final sum of squared deviations =  $2.5646125E+002$ Final sum of deviations =  $-7.5247469E+000$ Standard error of estimate =  $6.53785$ Average deviation =  $5.2399$ Maximum deviation for any observation = 8.44332 Proportion of variance explained  $(R^2) = 0.9988$  (99.88%) Adjusted coefficient of multiple determination  $(Ra^2) = 0.9986$  (99.86%) Durbin-Watson test for autocorrelation = 1.916

Warning: Covariance matrix could not be computed because the finite-difference Hessian was indefinite. Analysis completed  $14$ -Mar-2004 17:14. Runtime = 0.05 seconds.

---- Descriptive Statistics for Variables ----



---- Calculated Parameter Values ----





### Amitriptyline 1%, 0.4 mA/cm<sup>^2</sup>

1: Title "Aqueous layer equation"; 2: Variable time; // Cooling time in hr 3: Variable Qa; // Quantity thru skin in micrograms 4: Constant L=500\*10^-4;  $//$  Skin thickness in cm // Diffusion coefficient in aqueous layer 5: Parameter Da; // Diffusion coef:<br>6: Parameter C1; // Bulk concentration 7: Function Qa=  $Cl*L*(Da*time/L^2-1/6-2/pi^2*(cos(pi)*exp( Da*pi^22*time/L^2)+cos(pi*2)/4*exp(-Da*4*pi^22*time/L^2)+cos(pi*3)/9*exp(-Da*4*pi^22*time/L^2)$  $Da*9*pi^2*time/L^2)$ )); 8: Plot xlabel="Time (hr)",ylabel="Drug permeated (micrograms)"; 9: Data; Beginning computation... Stopped due to: Relative function convergence. ---- Final Results ---- NLREG version 6.1 Copyright (c) 1992-2004 Phillip H. Sherrod. Aqueous layer equation Number of observations = 8 Maximum allowed number of iterations  $= 500$ Convergence tolerance factor = 1.000000E-010 Stopped due to: Relative function convergence. Number of iterations performed = 242 Final sum of squared deviations = 2.9223007E+002 Final sum of deviations =  $-9.0032209E+000$ Standard error of estimate = 6.9789 Average deviation = 5.07336 Maximum deviation for any observation = 10.4809 Proportion of variance explained  $(R^2) = 0.9986$  (99.86%) Adjusted coefficient of multiple determination  $(Ra^2) = 0.9983$  (99.83%) Durbin-Watson test for autocorrelation = 2.022

Warning: Covariance matrix could not be computed because the finite-difference Hessian was indefinite. Analysis completed 14-Mar-2004 17:17. Runtime = 0.06 seconds.

---- Descriptive Statistics for Variables ----



--- Calculated Parameter Values ----





#### **Amitriptyline Control**

1: Title "Aqueous layer equation"; 2: Variable time; // Cooling time in hr 3: Variable Qa; // Quantity thru skin in micrograms 4: Constant  $\tilde{L} = 500 \times 10^{-2} - 4$ ; // Skin thickness in cm<br>5: Parameter Da; // Diffusion coefficient in aqueous layer 5: Parameter Da; 6: Parameter C1; // Bulk concentration 7: Function Qa= C1\*L\* (Da\*time/L^2-1/6-2/pi^2\* (cos (pi) \*exp(- $\text{Da*pi}^2$  \*time/L<sup>2</sup>2) +cos(pi\*2) /4\*exp(-Da\*4\*pi<sup>2</sup> \*time/L<sup>2</sup>2) +cos(pi\*3) /9\*exp(- $Da*9*pi^2*time/L^2))$ ; 8: Plot xlabel="Time (hr)", ylabel="Drug permeated (micrograms)";  $9: Data;$ Beginning computation... Error executing line 7: Function Qa= C1\*L\* (Da\*time/L^2-1/6-2/pi^2\* (cos (pi) \*exp(-Da\*pi^2\*time/L Error: Argument to exp function is too large (1950.97) Error executing line 7: Function Qa= C1\*L\* (Da\*time/L^2-1/6-2/pi^2\* (cos(pi)\*exp(-Da\*pi^2\*time/L Error: Arqument to exp function is too large (4389.68) Stopped due to: Relative function convergence. ---- Final Results ----NLREG version 6.1 Copyright (c) 1992-2004 Phillip H. Sherrod. Aqueous layer equation Number of observations =  $9$ Maximum allowed number of iterations = 500 Convergence tolerance factor =  $1.000000E-010$ Stopped due to: Relative function convergence. Number of iterations performed = 132 Final sum of squared deviations =  $2.9412881E+000$ Final sum of deviations =  $-1.1868429E+000$ Standard error of estimate = 0.648216 Average deviation =  $0.488224$ Maximum deviation for any observation = 1.12615 Proportion of variance explained  $(R^2) = 0.9964$  (99.64%) Adjusted coefficient of multiple determination (Ra^2) = 0.9959 (99.59%) Durbin-Watson test for autocorrelation = 2.558 Warning: Covariance matrix could not be computed because the finite-difference Hessian was indefinite. Analysis completed  $14$ -Mar-2004 16:06. Runtime = 0.11 seconds.

---- Descriptive Statistics for Variables ----



---- Calculated Parameter Values ----





### Clomipramine 0.5%, 0.1 mA/cm^2

1: Title "Aqueous layer equation";

2: Variable time; // Cooling time in hr 3: Variable Qa; // Quantity thru skin in micrograms 4: Constant L=500\*10^-4;<br>5: Parameter Da; // Diffusion coefficient in aqueous layer // Skin thickness in cm 6: Parameter C1; // Bulk concentration 7: Function Qa= C1\*L\* (Da\*time/L^2-1/6-2/pi^2\* (cos (pi) \*exp (-Da\*pi^2\*time/L^2)+cos(pi\*2)/4\*exp(-Da\*4\*pi^2\*time/L^2)+cos(pi\*3)/9\*exp(- $Da*9*pi^2*time/L^2))$ ; 8: Plot xlabel="Time (hr)", ylabel="Drug permeated (micrograms)";  $9: Data;$ Beginning computation... Stopped due to: Relative function convergence. ---- Final Results ----NLREG version 6.1 Copyright (c) 1992-2004 Phillip H. Sherrod. Aqueous layer equation Number of observations =  $9$ Maximum allowed number of iterations = 500 Convergence tolerance factor =  $1.000000E-010$ Stopped due to: Relative function convergence. Number of iterations performed =  $252$ Final sum of squared deviations =  $9.7682850E+001$ Final sum of deviations =  $6.3080725E+000$ Standard error of estimate =  $3.7356$ Average deviation =  $2.4816$ Maximum deviation for any observation = 7.91646 Proportion of variance explained  $(R^2) = 0.9930$  (99.30%) Adjusted coefficient of multiple determination  $(Ra^2) = 0.9920$  (99.20%) Durbin-Watson test for autocorrelation =  $2.005$ Warning: Covariance matrix could not be computed because the finite-difference Hessian was indefinite. Analysis completed  $14$ -Mar-2004 17:33. Runtime = 0.06 seconds. ---- Descriptive Statistics for Variables ----



---- Calculated Parameter Values ----





#### Clomipramine  $0.1\%$ ,  $0.1 \text{ mA/cm}^2$

1: Title "Aqueous layer equation"; 2: Variable time; // Cooling time in hr 3: Variable Qa; // Quantity thru skin in micrograms 4: Constant L=500\*10^-4; // Skin thickness in cm<br>5: Parameter Da; // Diffusion coefficient in aqueous layer 6: Parameter C1; // Bulk concentration 7: Function Qa= C1\*L\* (Da\*time/L^2-1/6-2/pi^2\* (cos (pi) \*exp (-Da\*pi^2\*time/L^2)+cos(pi\*2)/4\*exp(-Da\*4\*pi^2\*time/L^2)+cos(pi\*3)/9\*exp(- $Da*9*pi^2*time/L^2))$ ; 8: Plot xlabel="Time (hr)", ylabel="Drug permeated (micrograms)";  $9: Data;$ Beginning computation... Stopped due to: Relative function convergence. ---- Final Results ----NLREG version 6.1 Copyright (c) 1992-2004 Phillip H. Sherrod. Aqueous layer equation Number of observations =  $9$ Maximum allowed number of iterations = 500 Convergence tolerance factor =  $1.000000E-010$ Stopped due to: Relative function convergence. Number of iterations performed = 208 Final sum of squared deviations =  $1.2456287E+002$ Final sum of deviations =  $9.9853494E+000$ Standard error of estimate =  $4.21838$ Average deviation =  $3.10507$ Maximum deviation for any observation =  $6.99341$ Proportion of variance explained  $(R^2) = 0.9714$  (97.14%) Adjusted coefficient of multiple determination  $(Ra^2) = 0.9673$  (96.73%) Durbin-Watson test for autocorrelation = 0.995 Warning: Covariance matrix could not be computed because the finite-difference Hessian was indefinite.

Analysis completed  $14$ -Mar-2004 17:38. Runtime = 0.11 seconds.

---- Descriptive Statistics for Variables ----



---- Calculated Parameter Values ----





### Clomipramine 1%, 0.1 mA/cm^2

1: Title "Aqueous layer equation"; 2: Variable time; // Cooling time in hr 3: Variable Qa; // Quantity thru skin in micrograms 4: Constant L=500\*10^-4; // Skin thickness in cm 5: Parameter Da; // Diffusion coefficient in aqueous layer 6: Parameter C1; // Bulk concentration 7: Function Qa= Cl\*L\* (Da\*time/L^2-1/6-2/pi^2\* (cos (pi) \*exp (- $Da*pi^2*time/L^2) + cos(pi*2)/4*exp(-Da*4*pi^2*time/L^2) + cos(pi*3)/9*exp(-D2*4*pi^2)$  $Da*9*pi^2*time/L^2))$ ; 8: Plot xlabel="Time (hr)", ylabel="Drug permeated (micrograms)";  $9: Data:$ Beginning computation... Error executing line 7: Function Qa= C1\*L\* (Da\*time/L^2-1/6-2/pi^2\* (cos (pi) \*exp(-Da\*pi^2\*time/L Error: Argument to exp function is too large (979.203) Error executing line 7: Function Qa= C1\*L\* (Da\*time/L^2-1/6-2/pi^2\* (cos (pi) \*exp(- $Da * pi^2 * time/L$ Error: Argument to exp function is too large (529.692) Error executing line 7: Function Qa= Cl\*L\*(Da\*time/L^2-1/6-2/pi^2\*(cos(pi)\*exp(-Da\*pi^2\*time/L Error: Argument to exp function is too large (991.656) Error executing line 7: Function Qa= C1\*L\* (Da\*time/L^2-1/6-2/pi^2\* (cos (pi) \*exp(- $Da*pi^2*time/L$ Error: Argument to exp function is too large (2231.23) Error executing line 7: Function Qa= C1\*L\* (Da\*time/L^2-1/6-2/pi^2\* (cos (pi) \*exp(-Da\*pi^2\*time/L Error: Argument to exp function is too large (931.208) Error executing line 7: Function Qa= C1\*L\* (Da\*time/L^2-1/6-2/pi^2\* (cos (pi) \*exp(- $Da*pi^2*time/L$ Error: Argument to exp function is too large (562.399) Stopped due to: Relative function convergence.  $---$  Final Results  $---$ NLREG version 6.1 Copyright (c) 1992-2004 Phillip H. Sherrod. Aqueous layer equation Number of observations = 9 Maximum allowed number of iterations = 500 Convergence tolerance factor =  $1.000000E-010$ Stopped due to: Relative function convergence. Number of iterations performed =  $271$ Final sum of squared deviations =  $9.7451427E+001$ Final sum of deviations =  $3.5233566E+000$ Standard error of estimate =  $3.73117$ Average deviation =  $2.74922$ Maximum deviation for any observation =  $6.65513$ Proportion of variance explained  $(R^2) = 0.9948$  (99.48%) Adjusted coefficient of multiple determination  $(Ra^2) = 0.9940$  (99.40%) Durbin-Watson test for autocorrelation =  $1.220$ Warning: Covariance matrix could not be computed because the finite-difference Hessian was indefinite.

---- Descriptive Statistics for Variables ----

Analysis completed  $14$ -Mar-2004 18:27. Runtime = 0.11 seconds.



---- Calculated Parameter Values ----



Error executing line 7: Function Qa= C1\*L\* (Da\*time/L^2-1/6-2/pi^2\* (cos (pi) \*exp(-Da\*pi^2\*time/L Error: Argument to exp function is too large (555.096) Error executing line 7: Function Qa= C1\*L\* (Da\*time/L^2-1/6-2/pi^2\* (cos (pi) \*exp(-Da\*pi^2\*time/L Error: Argument to exp function is too large (1248.97) Error executing line 7: Function Qa= C1\*L\* (Da\*time/L^2-1/6-2/pi^2\* (cos (pi) \*exp(- $\mathtt{Da}\star\mathtt{pi}\char`2\star\mathtt{time}/\mathtt{L}$ Error: Argument to exp function is too large (558.608) Error executing line 7: Function Qa= C1\*L\* (Da\*time/L^2-1/6-2/pi^2\* (cos (pi) \*exp(- $Da * pi^2 * time/L$ Error: Argument to exp function is too large (640.285) Stopped due to: Relative function convergence.  $---$  Final Results  $---$ NLREG version 6.1 Copyright (c) 1992-2004 Phillip H. Sherrod. Aqueous layer equation Number of observations =  $9$ Maximum allowed number of iterations = 500 Convergence tolerance factor =  $1.000000E-010$ Stopped due to: Relative function convergence. Number of iterations performed = 235 Final sum of squared deviations =  $1.8086043E+002$ Final sum of deviations =  $9.8590568E+000$ Standard error of estimate =  $5.08303$ Average deviation =  $3.41423$ Maximum deviation for any observation =  $9.74235$ Proportion of variance explained  $(R^2) = 0.9912$  (99.12%) Adjusted coefficient of multiple determination  $(Ra^2) = 0.9900$  (99.00%) Durbin-Watson test for autocorrelation = 1.531

Warning: Covariance matrix could not be computed because the finite-difference Hessian was indefinite. Analysis completed  $14$ -Mar-2004 18:32. Runtime = 0.11 seconds.

---- Descriptive Statistics for Variables ----



---- Calculated Parameter Values ----





## **Clomipramine 0.1%, 0.2 mA/cm^2**

1: Title "Aqueous layer equation";<br>2: Variable time; // Cool // Cooling time in hr 3: Variable Qa; // Quantity thru skin in micrograms<br>4: Constant L=500\*10^-4; // Skin thickness in cm 4: Constant L=500\*10^-4; 5: Parameter Da;  $\frac{1}{2}$  // Diffusion coefficient in aqueous layer 6: Parameter C1; // Bulk concentration // Bulk concentration 7: Function Qa=  $Cl*L* (Da*time/L^2-1/6-2/pi^2* (cos(pi)*exp(-1/2))$ Da\*pi^2\*time/L^2)+cos(pi\*2)/4\*exp(-Da\*4\*pi^2\*time/L^2)+cos(pi\*3)/9\*exp(- $Da*9*pi^2*time/L^2)$ )); 8: Plot xlabel="Time (hr)",ylabel="Drug permeated (micrograms)"; 9: Data; Beginning computation... Error executing line 7: Function Qa= Cl\*L\*(Da\*time/L <sup>A</sup> 2-1/6-2/pi A 2\*(cos(pi)\*exp(-  $Da*pi^2*time/L$ Error: Argument to exp function is too large (639.326) Error executing line 7: Function Qa= Cl\*L\*(Da\*time/L^2-1/6-2/pi^2\*(cos(pi)\*exp(- $Da*pi^2*time/L$ Error: Argument to exp function is too large (1438.48) Error executing line 7: Function Qa= Cl\*L\*(Da\*time/L^2-1/6-2/pi^2\*(cos(pi)\*exp(- $Da * pi^2 * time/L$ Error: Argument to exp function is too large (603.632) Error executing line 7: Function Qa= Cl\*L\*(Da\*time/L^2-1/6-2/pi^2\*(cos(pi)\*exp(-Da\*pi^2\*time/L Error: Argument to exp function is too large (1358.17) Error executing line 7: Function Qa= Cl\*L\*(Da\*time/L^2-1/6-2/pi^2\*(cos(pi)\*exp(- $Da * pi^2 * time/L$ Error: Argument to exp function is too large (934.034) Error executing line 7: Function Qa=  $Cl^{\star}L^{\star}(Da^{\star}Lime/L^2-1/6-2/pi^{\star}2^{*}(cos(pi)*exp(-i\pi i))$  $Da * pi^2 * time/L$ Error: Argument to exp function is too large (912.722) Error executing line 7: Function Qa=  $Cl^{\star}L^{\star}$  (Da\*time/L^2-1/6-2/pi^2\* (cos(pi)\*exp(- $Da * pi^2 * time/L$ Error: Argument to exp function is too large (2053.62) Error executing line 7: Function Qa=  $Cl^{\star}L^{\star} (Da^{\star}$ time/L<sup>2</sup>2-1/6-2/pi<sup>2</sup>2\*(cos(pi)\*exp(-Da\*pi^2\*time/L Error: Argument to exp function is too large (861.832) Error executing line 7: Function  $Qa = C1 * L * (Da * time/L^2 - 1/6 - 2/pi^2 * (cos(pi) * exp(-1/6))$ Da\*pi^2\*time/L Error: Argument to exp function is too large (531.872) Stopped due to: Relative function convergence.  $---$  Final Results  $---$ NLREG version 6.1 Copyright (c) 1992-2004 Phillip H. Sherrod. Aqueous layer equation Number of observations = 9 Maximum allowed number of iterations = 500 Convergence tolerance factor = 1.000000E-010 Stopped due to: Relative function convergence. Number of iterations performed = 188 Final sum of squared deviations =  $7.8825876E+001$ Final sum of deviations =  $1.6649555E+000$ Standard error of estimate = 3.35572 Average deviation = 2.67774 Maximum deviation for any observation = 4.50932 Proportion of variance explained  $(R^2) = 0.9885$  (98.85%) Adjusted coefficient of multiple determination  $(Ra^2) = 0.9869$  (98.69%) Durbin-Watson test for autocorrelation = 2.538

Warning: Covariance matrix could not be computed because the finite-difference Hessian was indefinite. Analysis completed  $14$ -Mar-2004 18:37. Runtime = 0.11 seconds.



---- Calculated Parameter Values ----



---- Analysis of Variance ----



#### Clomipramine 1%, 0.2 mA/cm^2

1: Title "Aqueous layer equation"; 2: Variable time; // Cooling time in hr 3: Variable Qa; // Quantity thru skin in micrograms 4: Constant L=500\*10^-4; // Skin thickness in cm // Diffusion coefficient in aqueous layer 5: Parameter Da; 6: Parameter C1; // Bulk concentration 7: Function Qa= C1\*L\* (Da\*time/L^2-1/6-2/pi^2\* (cos (pi) \*exp (-Da\*pi^2\*time/L^2)+cos(pi\*2)/4\*exp(-Da\*4\*pi^2\*time/L^2)+cos(pi\*3)/9\*exp(- $Da*9*pi^2*time/L^2))$ ; 8: Plot xlabel="Time (hr)", ylabel="Drug permeated (micrograms)";  $9: Data;$ Beginning computation... Stopped due to: Relative function convergence. ---- Final Results ----NLREG version 6.1 Copyright (c) 1992-2004 Phillip H. Sherrod.

Aqueous layer equation Number of observations =  $9$ Maximum allowed number of iterations = 500 Convergence tolerance factor =  $1.000000E-010$ Stopped due to: Relative function convergence. Number of iterations performed = 218 Final sum of squared deviations =  $1.8471323E+002$ Final sum of deviations =  $8.3035381E+000$ Standard error of estimate =  $5.13689$ Average deviation =  $3.92323$ Maximum deviation for any observation =  $8.01804$ Proportion of variance explained  $(R^2) = 0.9921$  (99.21%) Adjusted coefficient of multiple determination  $(Ra^2) = 0.9910$  (99.10%) Durbin-Watson test for autocorrelation =  $1.871$ 

Warning: Covariance matrix could not be computed because the finite-difference Hessian was indefinite. Analysis completed  $14-Mar-2004$  18:41. Runtime = 0.05 seconds.
---- Descriptive Statistics for Variables ----



---- Calculated Parameter Values ----



---- Analysis of Variance ----



## Clomipramine 0.5%, 0.3 mA/cm^2

1: Title "Aqueous layer equation"; 2: Variable time; // Cooling time in hr 3: Variable Qa; // Quantity thru skin in micrograms 4: Constant L=500\*10^-4; // Skin thickness in cm // Diffusion coefficient in aqueous layer 5: Parameter Da; 6: Parameter C1; // Bulk concentration 7: Function Qa= C1\*L\* (Da\*time/L^2-1/6-2/pi^2\* (cos(pi)\*exp(-Da\*pi^2\*time/L^2)+cos(pi\*2)/4\*exp(-Da\*4\*pi^2\*time/L^2)+cos(pi\*3)/9\*exp(- $Da*9*pi^2*time/L^2))$ ; 8: Plot xlabel="Time (hr)", ylabel="Drug permeated (micrograms)";  $9: Data;$ Beginning computation... Stopped due to: Relative function convergence. ---- Final Results ----NLREG version 6.1 Copyright (c) 1992-2004 Phillip H. Sherrod. Aqueous layer equation Number of observations = 9 Maximum allowed number of iterations =  $500$ Convergence tolerance factor =  $1.000000E-010$ Stopped due to: Relative function convergence. Number of iterations performed = 202 Final sum of squared deviations =  $9.3550511E+001$ Final sum of deviations =  $-2.6479496E-001$ Standard error of estimate =  $3.65573$ Average deviation =  $2.53801$ Maximum deviation for any observation = 6.14425 Proportion of variance explained  $(R^2) = 0.9969$  (99.69%) Adjusted coefficient of multiple determination  $(Ra^2) = 0.9964$  (99.64%) Durbin-Watson test for autocorrelation =  $1.272$ Warning: Covariance matrix could not be computed because the finite-difference Hessian was indefinite. Analysis completed 14-Mar-2004 18:45. Runtime = 0.11 seconds.

---- Descriptive Statistics for Variables ----



warning: Covariance matrix could not be computed because<br>the finite-difference Hessian was indefinite.<br>Analysis completed 14-Mar-2004 18:51. Runtime = 0.06 seconds.



---- Calculated Parameter Values ----



---- Analysis of Variance ----



Clomipramine  $1\%$ , 0.3 mA/cm^2

1: Title "Aqueous layer equation"; 2: Variable time; // Cooling time in hr 3: Variable Qa; // Quantity thru skin in micrograms 4: Constant  $L=500*10^2-4$ ; // Skin thickness in cm 5: Parameter Da; // Diffusion coefficient in aqueous layer 6: Parameter C1; // Bulk concentration 7: Function Qa= C1\*L\* (Da\*time/L^2-1/6-2/pi^2\* (cos(pi)\*exp(- $\mathtt{Da} * \mathtt{pi}' 2 * \mathtt{time}/\mathtt{L}' 2) + \mathtt{cos}\left(\mathtt{pi} * 2\right)/4 * \mathtt{exp}\left(-\mathtt{Da} * 4 * \mathtt{pi}' 2 * \mathtt{time}/\mathtt{L}' 2\right) + \mathtt{cos}\left(\mathtt{pi} * 3\right)/9 * \mathtt{exp}\left(-\mathtt{m} * \mathtt{m}' 2\right)$  $Da*9*pi^2*time/L^2))$ ; 8: Plot xlabel="Time (hr)", ylabel="Drug permeated (micrograms)";  $9: Data;$ Beginning computation... Stopped due to: Relative function convergence. ---- Final Results ----NLREG version 6.1 Copyright (c) 1992-2004 Phillip H. Sherrod. Aqueous layer equation Number of observations =  $9$ Maximum allowed number of iterations = 500 Convergence tolerance factor =  $1.000000E-010$ Stopped due to: Relative function convergence. Number of iterations performed = 218 Final sum of squared deviations =  $1.6878953E+002$ Final sum of deviations =  $7.9779120E+000$ Standard error of estimate =  $4.91048$ Average deviation =  $3.58038$ Maximum deviation for any observation = 8.95871 Proportion of variance explained  $(R^2) = 0.9947$ (99.47%) Adjusted coefficient of multiple determination  $(Ra^2) = 0.9940$  (99.40%) Durbin-Watson test for autocorrelation =  $1.634$ 

```
Warning: Covariance matrix could not be computed because
the finite-difference Hessian was indefinite.
Analysis completed 14-Mar-2004 18:57. Runtime = 0.05 seconds.
```
---- Descriptive Statistics for Variables ----



---- Calculated Parameter Values ----



---- Analysis of Variance ----



Clomipramine 0.5%, 0.4 mA/cm^2

1: Title "Aqueous layer equation"; 2: Variable time; // Cooling time in hr 3: Variable Qa; // Quantity thru skin in micrograms 4: Constant L=500\*10^-4; // Skin thickness in cm // Diffusion coefficient in aqueous layer 5: Parameter Da; 6: Parameter C1; // Bulk concentration 7: Function Qa= Cl\*L\* (Da\*time/L^2-1/6-2/pi^2\* (cos (pi)\*exp(-Da\*pi^2\*time/L^2)+cos(pi\*2)/4\*exp(-Da\*4\*pi^2\*time/L^2)+cos(pi\*3)/9\*exp(- $Da*9*pi^2*time/L^2))$ ; 8: Plot xlabel="Time (hr)", ylabel="Drug permeated (micrograms)";  $9: Data;$ Beginning computation... Error executing line 7: Function Qa= C1\*L\* (Da\*time/L^2-1/6-2/pi^2\* (cos(pi)\*exp(-Da\*pi^2\*time/L Error: Argument to exp function is too large (559.349) Error executing line 7: Function Qa= C1\*L\* (Da\*time/L^2-1/6-2/pi^2\* (cos (pi) \*exp(-Da\*pi^2\*time/L Error: Argument to exp function is too large (883.083) Error executing line 7: Function Qa= C1\*L\* (Da\*time/L^2-1/6-2/pi^2\* (cos (pi) \*exp(- $Da*pi^2*time/L$ Error: Argument to exp function is too large (1986.94) Error executing line 7: Function Qa=  $Cl^{\star}L^{\star}$  (Da\*time/L^2-1/6-2/pi^2\* (cos (pi) \*exp(-Da\*pi^2\*time/L Error: Argument to exp function is too large (761.438) Error executing line 7: Function Qa= C1\*L\* (Da\*time/L^2-1/6-2/pi^2\* (cos (pi) \*exp(-Da\*pi^2\*time/L Error: Argument to exp function is too large (594.758) Stopped due to: Relative function convergence.  $---$  Final Results  $---$ NLREG version 6.1 Copyright (c) 1992-2004 Phillip H. Sherrod. Aqueous layer equation Number of observations =  $9$ Maximum allowed number of iterations = 500 Convergence tolerance factor = 1.000000E-010 Stopped due to: Relative function convergence. Number of iterations performed =  $230$ Final sum of squared deviations =  $5.4892846E+001$ Final sum of deviations =  $-4.9320779E-001$ Standard error of estimate =  $2.80033$ Average deviation =  $2.16673$ Maximum deviation for any observation =  $4.02908$ Proportion of variance explained  $(R^2) = 0.9986$  (99.86%)

Adjusted coefficient of multiple determination  $(Ra^2) = 0.9984$  (99.84%) Durbin-Watson test for autocorrelation = 1.526

Warning: Covariance matrix could not be computed because the finite-difference Hessian was indefinite. Analysis completed 14-Mar-2004 22:24. Runtime = 0.05 seconds.

---- Descriptive Statistics for Variables ----



---- Calculated Parameter Values ----



---- Analysis of Variance ----



**Clomipramine 0.1%, 0.4 mA/cm^2** 

1: Title "Aqueous layer equation";<br>2: Variable time; // Cool // Cooling time in hr 3: Variable Qa; // Quantity thru skin in micrograms<br>4: Constant L=500\*10^-4; // Skin thickness in cm 4: Constant L=500\*10^-4;<br>5: Parameter Da; // 5: Parameter Da; // Diffusion coefficient in aqueous layer<br>6: Parameter Cl; // Bulk concentration // Bulk concentration 7: Function Qa= Cl\*L\*(Da\*time/L^2-1/6-2/pi^2\*(cos(pi)\*exp(- $Da*pi^22*time/L^2)+cos(pi*2)/4*exp(-Da*4*pi^2*time/L^2)+cos(pi*3)/9*exp(-D+1)$  $Da*9*pi^2*time/L^2))$ ; 8: Plot xlabel="Time (hr)",ylabel="Drug permeated (micrograms)"; 9: Data; Beginning computation... Error executing line 7: Function Qa=  $Cl^*L^*(Da^*time/L^2-1/6-2/pi^2*(\cos(pt)*exp(-1/2+1/2))$  $Da * pi^2 * time/L$ Error: Argument to exp function is too large (690.957) Error executing line 7: Function Qa=  $Cl^*L^*(Da^*time/L^2-1/6-2/pi^2*(cos(pi)*exp(-nN+1))$  $Da*pi^2*time/L$ Error: Argument to exp function is too large (1554.65) Error executing line 7: Function Qa= C1\*L\*(Da\*time/L <sup>A</sup> 2-1/6-2/pi <sup>A</sup> 2\*(cos(pi)\*exp(-  $Da * pi^2 * time/L$ Error: Argument to exp function is too large (864.767) Stopped due to: Relative function convergence.

 $---$  Final Results  $---$ NLREG version 6.1 Copyright (c) 1992-2004 Phillip H. Sherrod.

Aqueous layer equation Number of observations = 9 Maximum allowed number of iterations = 500 Convergence tolerance factor = 1.000000E-010 Stopped due to: Relative function convergence. Number of iterations performed =  $253$ Final sum of squared deviations =  $4.3319788E+001$ Final sum of deviations =  $-4.8491571E+000$ Standard error of estimate =  $2.48768$ Average deviation =  $1.70732$ Maximum deviation for any observation =  $4.57979$ Proportion of variance explained  $(R^2) = 0.9990$  (99.90%) Adjusted coefficient of multiple determination (Ra^2) = 0.9989 (99.89%) Durbin-Watson test for autocorrelation = 1.523

Warning: Covariance matrix could not be computed because the finite-difference Hessian was indefinite. Analysis completed  $14$ -Mar-2004 22:26. Runtime = 0.06 seconds.

---- Descriptive Statistics for Variables ----



---- Calculated Parameter Values ----





## Clomipramine 1%, 0.4 mA/cm^2

1: Title "Aqueous layer equation"; 2: Variable time; (2001ing time in hr<br>3: Variable Qa; // Quantity thru skin in micrograms // Cooling time in hr // Skin thickness in cm 4: Constant L=500\*10^-4; // Diffusion coefficient in aqueous layer 5: Parameter Da; 6: Parameter C1; // Bulk concentration 7: Function Qa= C1\*L\* (Da\*time/L^2-1/6-2/pi^2\* (cos (pi) \*exp (- $Da*pi^2*time/L^2) + cos(pi*2)/4*exp(-Da*4*pi^2*time/L^2) + cos(pi*3)/9*exp(-b*2)$  $Da*9*pi^2*time/L^2))$ ; 8: Plot xlabel="Time (hr)", ylabel="Drug permeated (micrograms)";  $9: Data;$ Beginning computation... Stopped due to: Relative function convergence. ---- Final Results ----NLREG version 6.1 Copyright (c) 1992-2004 Phillip H. Sherrod. Aqueous layer equation Number of observations =  $9$ 

Maximum allowed number of iterations = 500 Convergence tolerance factor =  $1.000000E-010$ Stopped due to: Relative function convergence. Number of iterations performed =  $245$ Final sum of squared deviations =  $9.0199496E+001$ Final sum of deviations =  $-4.3002940E+000$ 

Standard error of estimate = 3.58966 Average deviation  $= 2.60861$ Maximum deviation for any observation =  $5.49494$ Proportion of variance explained  $(R^2) = 0.9978$  (99.78%) Adjusted coefficient of multiple determination (Ra'2) = 0.9975 (99.75%) Durbin-Watson test for autocorrelation = 1.387

Warning: Covariance matrix could not be computed because the finite-difference Hessian was indefinite. Analysis completed  $14$ -Mar-2004 22:29. Runtime = 0.11 seconds.

---- Descriptive Statistics for Variables ----



---- Calculated Parameter Values ----



---- Analysis of Variance ----



#### **Clomipramine Control**

```
1: Title "Aqueous layer equation";<br>2: Variable time; // Cool
                                  // Cooling time in hr
   3: Variable Qa; // Quantity thru skin in micrograms<br>4: Constant L = 500*10^2 - 4; // Skin thickness
                                            1/ Skin thickness in cm
   5: Parameter Da; \frac{1}{2} // Diffusion coefficient in aqueous layer 6: Parameter C1; // Bulk concentration
                         // Bulk concentration
   7: Function Qa= Cl*L* (Da*time/L^2-1/6-2/pi^2* (cos(pi)*exp(-1/6-2/4))Da*pi^2*time/L^2)+cos(pi*2)/4*exp(-Da*4*pi^2*time/L^2)+cos(pi*3)/9*exp(-D+2*)Da*9*pi^2*time/L^2)));
   8: Plot xlabel="Time (hr)",ylabel="Drug permeated (micrograms)";
   9: Data;
Beginning computation...
Error executing line 7: Function Qa= Cl^*L^*(Da^*time/L^2-1/6-2/pi^2*(cos(pi)*exp(-ni+1/2))Da*pi^2*time/L
Error: Argument to exp function is too large (837.928)
Error executing line 7: Function Qa= Cl*L* (Da*time/L^2-1/6-2/pi^2* (cos(pi)*exp(-1/6-2/2pi))^2)Da*pi^2*time/L
Error: Argument to exp function is too large (3351.71)
Error executing line 7: Function Qa= Cl*L* (Da*time/L^2-1/6-2/pi^2* (cos(pi)*exp(-ni+1/2))Da*pi^2*time/L
Error: Argument to exp function is too large (7541.36)
```
Error executing line 7: Function Qa=  $Cl^*L^*(Da*time/L^2-1/6-2/pi^2*(\cos(pi)*exp(-n+1/2+1/6-2/2))$  $Da * pi^2 * time/L$ Error: Argument to exp function is too large (559.447) Stopped due to: Relative function convergence.

---- Final Results ----NLREG version 6.1 Copyright (c) 1992-2004 Phillip H. Sherrod.

Aqueous layer equation Number of observations =  $9$ Maximum allowed number of iterations = 500 Convergence tolerance factor =  $1.000000E-010$ Stopped due to: Relative function convergence. Number of iterations performed = 112 Final sum of squared deviations =  $7.7923479E+000$ Final sum of deviations =  $-1.6335173E+000$ Standard error of estimate =  $1.05508$ Average deviation =  $0.66161$ Maximum deviation for any observation = 2.11871 Proportion of variance explained  $(R^2) = 0.9700$  (97.00%) Adjusted coefficient of multiple determination  $(Ra^2) = 0.9657$  (96.57%) Durbin-Watson test for autocorrelation = 1.627

Warning: Covariance matrix could not be computed because the finite-difference Hessian was indefinite. Analysis completed  $14$ -Mar-2004 22:31. Runtime = 0.06 seconds.







## Nortriptyline 0.5%, 0.1 mA/cm^2

Stopped due to: Relative function convergence.

1: Title "Aqueous layer equation"; 2: Variable time; // Cooling time in hr 3: Variable Qa; // Quantity thru skin in micrograms 4: Constant L=500\*10^-4; // Skin thickness in cm // Diffusion coefficient in aqueous layer 5: Parameter Da; 6: Parameter C1; // Bulk concentration 7: Function Qa= C1\*L\* (Da\*time/L^2-1/6-2/pi^2\* (cos(pi)\*exp(- $Da * pi^2 * time/L^2$  +  $cos(pi * 2) / 4 * exp(-Da * 4 * pi^2 * time/L^2) + cos(pi * 3) / 9 * exp( Da*9*pi^2*time/L^2))$ ; 8: Plot xlabel="Time (hr)", ylabel="Drug permeated (micrograms)";  $9: Data;$ Beginning computation... Stopped due to: Relative function convergence.  $---$  Final Results  $---$ NLREG version 6.1 Copyright (c) 1992-2004 Phillip H. Sherrod. Aqueous layer equation Number of observations =  $10$ Maximum allowed number of iterations = 500 Convergence tolerance factor =  $1.000000E-010$ 

Number of iterations performed =  $201$ Final sum of squared deviations =  $7.8049756E+002$ Final sum of deviations =  $1.1125482E+000$ Standard error of estimate =  $9.87736$ Average deviation =  $7.89258$ Maximum deviation for any observation = 12.892 Proportion of variance explained  $(R^2) = 0.9857$  (98.57%) Adjusted coefficient of multiple determination  $(Ra^2) = 0.9839$  (98.39%) Durbin-Watson test for autocorrelation =  $1.201$ 

Warning: Covariance matrix could not be computed because the finite-difference Hessian was indefinite. Analysis completed 14-Mar-2004 22:11. Runtime = 0.11 seconds.

---- Descriptive Statistics for Variables ----



---- Calculated Parameter Values ----



---- Analysis of Variance ----



# Nortriptyline 0.1%, 0.1 mA/cm^2

1: Title "Aqueous layer equation"; 2: Variable time; // Cooling time in hr 3: Variable Qa; // Quantity thru skin in micrograms // Skin thickness in cm 4: Constant L=500\*10^-4; 5: Parameter Da; // Diffusion coefficient in aqueous layer // Bulk concentration 6: Parameter C1; 7: Function Qa= C1\*L\* (Da\*time/L^2-1/6-2/pi^2\* (cos (pi)\*exp(-Da\*pi^2\*time/L^2)+cos(pi\*2)/4\*exp(-Da\*4\*pi^2\*time/L^2)+cos(pi\*3)/9\*exp(- $Da*9*pi^2*time/L^2))$ ; 8: Plot xlabel="Time (hr)", ylabel="Drug permeated (micrograms)";  $9: Data;$ Beginning computation... Error executing line 7: Function Qa= C1\*L\* (Da\*time/L^2-1/6-2/pi^2\* (cos (pi) \*exp(-Da\*pi^2\*time/L Error: Argument to exp function is too large (695.429) Error executing line 7: Function Qa= C1\*L\* (Da\*time/L^2-1/6-2/pi^2\* (cos(pi)\*exp(-Da\*pi^2\*time/L Error: Argument to exp function is too large (1564.71) Error executing line 7: Function Qa= C1\*L\* (Da\*time/L^2-1/6-2/pi^2\* (cos (pi) \*exp(-Da\*pi^2\*time/L Error: Argument to exp function is too large (601.323) Error executing line 7: Function Qa= C1\*L\* (Da\*time/L^2-1/6-2/pi^2\* (cos (pi) \*exp(-Da\*pi^2\*time/L

Error: Argument to exp function is too large (598.137) Stopped due to: Both parameter and relative function convergence.

 $---$  Final Results  $---$ NLREG version 6.1 Copyright (c) 1992-2004 Phillip H. Sherrod.

Aqueous layer equation Number of observations =  $9$ Maximum allowed number of iterations =  $500$ Convergence tolerance factor =  $1.000000E-010$ Stopped due to: Both parameter and relative function convergence. Number of iterations performed =  $200$ Final sum of squared deviations =  $5.0375094E+002$ Final sum of deviations =  $4.7724518E+000$ Standard error of estimate =  $8.48318$ Average deviation =  $6.49554$ Maximum deviation for any observation = 13.2956 Proportion of variance explained  $(R^2) = 0.9903$  (99.03%) Adjusted coefficient of multiple determination  $(Ra^2) = 0.9889$  (98.89%) Durbin-Watson test for autocorrelation = 1.641

Warning: Covariance matrix could not be computed because the finite-difference Hessian was indefinite. Analysis completed 14-Mar-2004 22:15. Runtime = 0.06 seconds.



#### Nortriptyline 1%, 0.1 mA/cm^2

1: Title "Aqueous layer equation"; 2: Variable time; // Cooling time in hr 3: Variable Qa; // Quantity thru skin in micrograms 4: Constant L=500\*10^-4; // Skin thickness in cm // Diffusion coefficient in aqueous layer 5: Parameter Da; // Bulk concentration 6: Parameter C1; 7: Function Qa= C1\*L\* (Da\*time/L^2-1/6-2/pi^2\* (cos (pi) \*exp(- $Da*pi^22*time/L^2)+cos(p1*2)/4*exp(-Da*4*pi^2*time/L^2)+cos(p1*3)/9*exp( Da*9*pi^2*time/L^2))$ ; 8: Plot xlabel="Time (hr)", ylabel="Drug permeated (micrograms)";  $9: Data;$ Beginning computation...

Error executing line 7: Function Qa= C1\*L\* (Da\*time/L^2-1/6-2/pi^2\* (cos (pi) \*exp(- $Da*pi^2*time/L$ Error: Argument to exp function is too large (515.978) Error executing line 7: Function Qa=  $Cl^{\star}L^{\star}$  (Da\*time/L^2-1/6-2/pi^2\* (cos(pi)\*exp(-Da\*pi^2\*time/L

Error executing line 7: Function Qa= C1\*L\* (Da\*time/L^2-1/6-2/pi^2\* (cos (pi) \*exp(-Da\*pi^2\*time/L Error: Arqument to exp function is too large (581.856) Stopped due to: Relative function convergence.

 $---$  Final Results  $---$ NLREG version 6.1 Copyright (c) 1992-2004 Phillip H. Sherrod.

Aqueous layer equation Number of observations =  $9$ Maximum allowed number of iterations = 500 Convergence tolerance factor =  $1.000000E-010$ Stopped due to: Relative function convergence. Number of iterations performed = 238 Final sum of squared deviations =  $1.0158489E+003$ Final sum of deviations =  $-9.5771445E+000$ Standard error of estimate = 12.0466 Average deviation =  $8.60352$ Maximum deviation for any observation =  $19.0787$ Proportion of variance explained  $(R^2) = 0.9805$  $(98.05)$ Adjusted coefficient of multiple determination (Ra^2) = 0.9777 (97.77%) Durbin-Watson test for autocorrelation = 1.720

Warning: Covariance matrix could not be computed because the finite-difference Hessian was indefinite. Analysis completed  $14$ -Mar-2004 22:16. Runtime = 0.05 seconds.







# Nortriptyline 0.5%, 0.2 mA/cm^2

1: Title "Aqueous layer equation"; 2: Variable time; // Cooling time in hr 3: Variable Qa; // Quantity thru skin in micrograms 4: Constant L=500\*10^-4; // Skin thickness in cm // Diffusion coefficient in aqueous layer 5: Parameter Da; // Bulk concentration 6: Parameter C1; 7: Function Qa= C1\*L\* (Da\*time/L^2-1/6-2/pi^2\* (cos (pi) \*exp (- $Da*pi^2*time/L^2) + cos(pi*2)/4*exp(-Da*4*pi^2*time/L^2) + cos(pi*3)/9*exp(-b*3)$  $Da*9*pi^2*time/L^2))$ ; 8: Plot xlabel="Time (hr)", ylabel="Drug permeated (micrograms)";  $9: Data;$ 

Beginning computation... Stopped due to: Relative function convergence.  $---$  Final Results  $---$ 

NLREG version 6.1 Copyright (c) 1992-2004 Phillip H. Sherrod.

Aqueous layer equation Number of observations =  $9$ Maximum allowed number of iterations = 500 Convergence tolerance factor =  $1.000000E-010$ Stopped due to: Relative function convergence. Number of iterations performed = 242 Final sum of squared deviations =  $8.6092709E+002$ Final sum of deviations =  $-4.3780221E+000$ Standard error of estimate = 11.0901 Average deviation =  $8.64707$ Maximum deviation for any observation = 16.8351 Proportion of variance explained  $(R^2) = 0.9934$  (99.34%) Adjusted coefficient of multiple determination  $(Ra^2) = 0.9925$  (99.25%) Durbin-Watson test for autocorrelation = 1.975

Warning: Covariance matrix could not be computed because the finite-difference Hessian was indefinite. Analysis completed 20-Mar-2004 23:57. Runtime = 0.11 seconds.

---- Descriptive Statistics for Variables ----



---- Calculated Parameter Values ----

Initial guess Final estimate Parameter Da 1 0.000100028247  $C1$  $1 -$ 42996.3147

---- Analysis of Variance ----



#### Nortriptyline  $0.1\%$ ,  $0.2 \text{ mA/cm}^2$

1: Title "Aqueous layer equation"; 2: Variable time; // Cooling time in hr 3: Variable Qa; // Quantity thru skin in micrograms 2. Constant L=500\*10^-4;<br>  $\frac{1}{2}$  // Skin thickness in cm<br>
5: Parameter Da;<br>  $\frac{1}{2}$  // Diffusion coefficient in aqueous layer<br>
6: Parameter C1; // Bulk concentration 7: Function Qa=  $Cl * L * (Da * time/L^2 - 1/6 - 2/pi^2 * (cos(pi) * exp(-1/6))$  $Da*pi^22*time/L^2)+cos(p1*2)/4*exp(-Da*4*pi^2*time/L^2)+cos(p1*3)/9*exp( Da*9*pi^2*time/L^2))$ ; 8: Plot xlabel="Time (hr)", ylabel="Drug permeated (micrograms)";  $9: Data;$ 

Beginning computation... Stopped due to: Relative function convergence.

 $---$  Final Results  $---$ 

NLREG version 6.1

Copyright (c) 1992-2004 Phillip H. Sherrod.

Aqueous layer equation Number of observations =  $9$ Maximum allowed number of iterations = 500 Convergence tolerance factor =  $1.000000E-010$ Stopped due to: Relative function convergence. Number of iterations performed = 238 Final sum of squared deviations =  $3.8024210E+002$ Final sum of deviations =  $-9.1110479E-001$ Standard error of estimate =  $7.37023$ Average deviation =  $5.43786$ Maximum deviation for any observation = 12.1438 Proportion of variance explained  $(R^2) = 0.9965$  (99.65%) Adjusted coefficient of multiple determination  $(Ra^2) = 0.9960$  (99.60%) Durbin-Watson test for autocorrelation = 1.766

Warning: Covariance matrix could not be computed because the finite-difference Hessian was indefinite. Analysis completed 21-Mar-2004 00:07. Runtime = 0.05 seconds.

---- Descriptive Statistics for Variables ----



---- Calculated Parameter Values ----



---- Analysis of Variance ----



## Nortriptyline 1%, 0.2 mA/cm^2

1: Title "Aqueous layer equation"; 2: Variable time; // Cooling time in hr 3: Variable Qa; // Quantity thru skin in micrograms 4: Constant L=500\*10^-4; // Skin thickness in cm // Diffusion coefficient in aqueous layer 5: Parameter Da; // Bulk concentration 6: Parameter C1; 7: Function Qa= C1\*L\* (Da\*time/L^2-1/6-2/pi^2\* (cos(pi)\*exp(-Da\*pi^2\*time/L^2)+cos(pi\*2)/4\*exp(-Da\*4\*pi^2\*time/L^2)+cos(pi\*3)/9\*exp(- $Da*9*pi^2*time/L^2))$ ; 8: Plot xlabel="Time (hr)", ylabel="Drug permeated (micrograms)";  $9: Data;$ Beginning computation... Stopped due to: Relative function convergence.

---- Final Results ----

NLREG version 6.1 Copyright (c) 1992-2004 Phillip H. Sherrod.

Aqueous layer equation

Number of observations =  $9$ Maximum allowed number of iterations = 500 Convergence tolerance factor =  $1.000000E-010$ Stopped due to: Relative function convergence. Number of iterations performed = 124 Final sum of squared deviations =  $2.0129181E+003$ Final sum of deviations =  $-3.9763705E+000$ Standard error of estimate =  $16.9576$ Average deviation =  $13.0857$ Maximum deviation for any observation = 29.6808 Proportion of variance explained  $(R^2) = 0.9834$  (98.34%) Adjusted coefficient of multiple determination  $(Ra^2) = 0.9811$  (98.11%) Durbin-Watson test for autocorrelation = 2.340

Warning: Covariance matrix could not be computed because the finite-difference Hessian was indefinite. Analysis completed 20-Mar-2004 23:59. Runtime = 0.06 seconds.

---- Descriptive Statistics for Variables ----



---- Calculated Parameter Values ----



---- Analysis of Variance ----



#### Nortriptyline 0.5%, 0.3 mA/cm^2

1: Title "Aqueous layer equation";

// Cooling time in hr 2: Variable time;

3: Variable Qa; // Quantity thru skin in micrograms

4: Constant L=500\*10^-4; // Skin thickness in cm

// Diffusion coefficient in aqueous layer 5: Parameter Da;

// Bulk concentration 6: Parameter C1;

7: Function Qa= Cl\*L\*(Da\*time/L^2-1/6-2/pi^2\*(cos(pi)\*exp(-

Da\*pi^2\*time/L^2)+cos(pi\*2)/4\*exp(-Da\*4\*pi^2\*time/L^2)+cos(pi\*3)/9\*exp(- $Da*9*pi^2*time/L^2))$ ;

8: Plot xlabel="Time (hr)", ylabel="Drug permeated (micrograms)";  $9: Data;$ 

Beginning computation...

Error executing line 7: Function Qa= C1\*L\* (Da\*time/L^2-1/6-2/pi^2\* (cos (pi) \*exp(-Da\*pi^2\*time/L Error: Argument to exp function is too large (889.988) Stopped due to: Relative function convergence.

 $---$  Final Results  $---$ 

NLREG version 6.1 Copyright (c) 1992-2004 Phillip H. Sherrod.

Aqueous layer equation Number of observations =  $9$ Maximum allowed number of iterations = 500 Convergence tolerance factor = 1.000000E-010 Stopped due to: Relative function convergence. Number of iterations performed = 229 Final sum of squared deviations =  $1.3082240E+003$ Final sum of deviations =  $-3.5035557E+000$ Standard error of estimate =  $13.6707$ Average deviation =  $11.2092$ Maximum deviation for any observation = 17.6665 Proportion of variance explained  $(R^2) = 0.9953$  (99.53%) Adjusted coefficient of multiple determination  $(Ra^2) = 0.9946$  (99.46%) Durbin-Watson test for autocorrelation =  $1.423$ 

Warning: Covariance matrix could not be computed because the finite-difference Hessian was indefinite. Analysis completed  $21$ -Mar-2004 00:00. Runtime = 0.11 seconds.

---- Descriptive Statistics for Variables ----



---- Calculated Parameter Values ----



---- Analysis of Variance ----



Nortriptyline 0.1 %, 0.3 mA/cm^2

1: Title "Aqueous layer equation"; 2: Variable time; // Cooling time in hr 3: Variable Qa; // Quantity thru skin in micrograms 4: Constant L=500\*10^-4; // Skin thickness in cm 5: Parameter Da; // Diffusion coefficient in aqueous layer 6: Parameter C1; // Bulk concentration 7: Function Qa= C1\*L\* (Da\*time/L^2-1/6-2/pi^2\* (cos (pi) \*exp (-Da\*pi^2\*time/L^2)+cos(pi\*2)/4\*exp(-Da\*4\*pi^2\*time/L^2)+cos(pi\*3)/9\*exp(- $Da*9*pi^2*time/L^2))$ ; 8: Plot xlabel="Time (hr)", ylabel="Drug permeated (micrograms)";  $9: Data;$ Beginning computation...

Error executing line 7: Function Qa= C1\*L\* (Da\*time/L^2-1/6-2/pi^2\* (cos (pi) \*exp(-Da\*pi^2\*time/L Error: Argument to exp function is too large (844.623) Stopped due to: Relative function convergence.

 $---$  Final Results  $---$ 

NLREG version 6.1 Copyright (c) 1992-2004 Phillip H. Sherrod. Aqueous layer equation Number of observations =  $9$ Maximum allowed number of iterations = 500 Convergence tolerance factor =  $1.000000E-010$ Stopped due to: Relative function convergence. Number of iterations performed = 210 Final sum of squared deviations =  $1.5331897E+003$ Final sum of deviations =  $5.4305597E-001$ Standard error of estimate =  $14.7996$ Average deviation =  $11.9369$ Maximum deviation for any observation =  $21.0218$ Proportion of variance explained  $(R^2) = 0.9944$  $(99.44)$ Adjusted coefficient of multiple determination  $(Ra^2) = 0.9936$  (99.36%) Durbin-Watson test for autocorrelation =  $1.272$ 

Warning: Covariance matrix could not be computed because the finite-difference Hessian was indefinite. Analysis completed  $21$ -Mar-2004 00:01. Runtime = 0.11 seconds.

---- Descriptive Statistics for Variables ----



---- Calculated Parameter Values ----



---- Analysis of Variance ----



Nortriptyline 1%, 0.3 mA/cm^2

1: Title "Aqueous layer equation";

2: Variable time; // Cooling time in hr

3: Variable Qa; // Quantity thru skin in micrograms

// Skin thickness in cm 4: Constant L=500\*10^-4;

// Diffusion coefficient in aqueous layer 5: Parameter Da;

6: Parameter C1; // Bulk concentration

7: Function Qa= C1\*L\* (Da\*time/L^2-1/6-2/pi^2\* (cos (pi) \*exp (-

Da\*pi^2\*time/L^2)+cos(pi\*2)/4\*exp(-Da\*4\*pi^2\*time/L^2)+cos(pi\*3)/9\*exp(- $Da*9*pi^2*time/L^2)$ ));

8: Plot xlabel="Time (hr)", ylabel="Drug permeated (micrograms)";  $9: Data;$ 

Beginning computation...

Error executing line 7: Function Qa= C1\*L\* (Da\*time/L^2-1/6-2/pi^2\* (cos (pi) \*exp(-Da\*pi^2\*time/L Error: Argument to exp function is too large (588.569) Error executing line 7: Function Qa= C1\*L\* (Da\*time/L^2-1/6-2/pi^2\* (cos (pi) \*exp (- $Da*pi^2*time/L$ 

Error: Argument to exp function is too large (1324.28)

Error executing line 7: Function Qa=  $Cl^{\star}L^{\star}$  (Da\*time/L^2-1/6-2/pi^2\*(cos(pi)\*exp(- $Da * pi^2 * time/L$ Error: Argument to exp function is too large (591.184) Error executing line 7: Function Qa=  $Cl^*L^*(Da*time/L^2-1/6-2/pi^2* (cos(pi)*exp(-n-1/6-2/2))$  $Da * pi^2 * time/L$ Error: Argument to exp function is too large (1136.37) Error executing line 7: Function Qa=  $Cl^*L^*(Da*time/L^2-1/6-2/pi^2* (cos(pi)*exp(-n-1/2))$  $Da * pi^2 * time/L$ Error: Argument to exp function is too large (2556.83) Error executing line 7: Function Qa=  $Cl^{\star}L^{\star} (Da^{\star}time/L^2 - 1/6 - 2/pi^2 \star (cos(pi) *exp(-n-1/2))$  $Da*pi^2*time/L$ Error: Argument to exp function is too large (1048.64) Error executing line 7: Function Qa=  $Cl^{\star}L^{\star}$  ( $Da^{\star}$ time/ $L^{\star}2-1/6-2$ /pi $\hat{ }$ 2\* (cos(pi)\*exp(- $Da * pi^2 * time/L$ Error: Argument to exp function is too large (589.087) Stopped due to: Relative function convergence. ---- Final Results ---- NLREG version 6.1 Copyright (c) 1992-2004 Phillip H. Sherrod. Aqueous layer equation Number of observations = 9 Maximum allowed number of iterations = 500 Convergence tolerance factor = 1.000000E-010 Stopped due to: Relative function convergence. Number of iterations performed = 218 Final sum of squared deviations = 1.8814887E+003 Final sum of deviations =  $6.7507443E+000$ Standard error of estimate = 16.3946 Average deviation = 12.4069 Maximum deviation for any observation =  $25.6267$ Proportion of variance explained  $(R^2) = 0.9933$  (99.33%) Adjusted coefficient of multiple determination  $(Ra^2) = 0.9923$  (99.23%) Durbin-Watson test for autocorrelation =  $1.265$ Warning: Covariance matrix could not be computed because the finite-difference Hessian was indefinite. Analysis completed 21-Mar-2004 00:09. Runtime = 0.06 seconds. ---- Descriptive Statistics for Variables ----



Parameter Initial guess Final estimate Da 1 0.000113679205<br>C1 1 50403.8657 C1 1 50403.8657

#### ---- Analysis of Variance ----



# Nortriptyline 0.5%, 0.4 mA/cm^2 1: Title "Aqueous layer equation"; 2: Variable time; // Cooling time in hr 3: Variable Qa; // Quantity thru skin in micrograms 4: Constant L=500\*10^-4;<br>
5: Parameter Da;<br>
6: Parameter C1; // Bulk concentration<br>
6: Parameter C1; // Bulk concentration 7: Function Qa= C1\*L\* (Da\*time/L^2-1/6-2/pi^2\* (cos(pi)\*exp(-Da\*pi^2\*time/L^2)+cos(pi\*2)/4\*exp(-Da\*4\*pi^2\*time/L^2)+cos(pi\*3)/9\*exp(- $Da*9*pi^2*time/L^2))$ ; 8: Plot xlabel="Time (hr)", ylabel="Drug permeated (micrograms)";  $9: Data;$ Beginning computation... Error executing line 7: Function Qa= C1\*L\* (Da\*time/L^2-1/6-2/pi^2\* (cos(pi)\*exp(-Da\*pi^2\*time/L Error: Argument to exp function is too large (1512.35) Error executing line 7: Function Qa= C1\*L\*(Da\*time/L^2-1/6-2/pi^2\*(cos(pi)\*exp(-Da\*pi^2\*time/L Error: Argument to exp function is too large (3402.78) Error executing line 7: Function Qa= C1\*L\* (Da\*time/L^2-1/6-2/pi^2\* (cos (pi) \*exp(-Da\*pi^2\*time/L Error: Argument to exp function is too large (559.665) Error executing line 7: Function Qa= C1\*L\* (Da\*time/L^2-1/6-2/pi^2\* (cos (pi) \*exp(-Da\*pi^2\*time/L Error: Argument to exp function is too large (1259.25) Error executing line 7: Function Qa= C1\*L\* (Da\*time/L^2-1/6-2/pi^2\* (cos(pi)\*exp(-Da\*pi^2\*time/L Error: Argument to exp function is too large (562.443) Stopped due to: Relative function convergence. ---- Final Results ----NLREG version 6.1 Copyright (c) 1992-2004 Phillip H. Sherrod. Aqueous layer equation Number of observations =  $9$ Maximum allowed number of iterations = 500 Convergence tolerance factor =  $1.000000E-010$ Stopped due to: Relative function convergence. Number of iterations performed =  $262$ Final sum of squared deviations =  $1.0941712E+004$ Final sum of deviations =  $4.5631002E+001$ Standard error of estimate = 39.5361 Average deviation =  $32.6294$ Maximum deviation for any observation = 52.3435 Proportion of variance explained  $(R^2) = 0.9792$  (97.92%) Adjusted coefficient of multiple determination  $(Ra^2) = 0.9762$  (97.62%) Durbin-Watson test for autocorrelation =  $1.242$ Warning: Covariance matrix could not be computed because the finite-difference Hessian was indefinite. Analysis completed 21-Mar-2004 00:10. Runtime = 0.11 seconds. ---- Descriptive Statistics for Variables ----

Variable Minimum value Maximum value Mean value Standard dev. 8 12.738613 <mark>8</mark><br>758.62 247.8367 256.3604 time  $\overline{0}$ 0a  $\Omega$ 

---- Calculated Parameter Values ----



---- Analysis of Variance ----



#### Nortriptyline 0.1%, 0.4 mA/cm^2

1: Title "Aqueous layer equation"; 2: Variable time; // Cooling time in hr 3: Variable Qa; // Quantity thru skin in micrograms // Skin thickness in cm 4: Constant L=500\*10^-4; // Diffusion coefficient in aqueous layer 5: Parameter Da; 6: Parameter C1; // Bulk concentration 7: Function Qa= C1\*L\* (Da\*time/L^2-1/6-2/pi^2\* (cos (pi) \*exp(-Da\*pi^2\*time/L^2)+cos(pi\*2)/4\*exp(-Da\*4\*pi^2\*time/L^2)+cos(pi\*3)/9\*exp(- $Da*9*pi^2*time/L^2))$ ; 8: Plot xlabel="Time (hr)", ylabel="Drug permeated (micrograms)";  $9: Data;$ Beginning computation... Error executing line 7: Function Qa= C1\*L\* (Da\*time/L^2-1/6-2/pi^2\* (cos (pi) \*exp(-Da\*pi^2\*time/L Error: Argument to exp function is too large (1099.17) Stopped due to: Relative function convergence. ---- Final Results ----NLREG version 6.1 Copyright (c) 1992-2004 Phillip H. Sherrod. Aqueous layer equation Number of observations =  $9$ Maximum allowed number of iterations = 500 Convergence tolerance factor =  $1.000000E-010$ Stopped due to: Relative function convergence. Number of iterations performed =  $298$ Final sum of squared deviations =  $8.8309564E+003$ Final sum of deviations =  $4.9968661E+001$ Standard error of estimate = 35.5185 Average deviation =  $29.6055$ Maximum deviation for any observation = 47.0195 Proportion of variance explained  $(R^2) = 0.9845$  (98.45%) Adjusted coefficient of multiple determination  $(Ra^2) = 0.9823$  (98.23%) Durbin-Watson test for autocorrelation = 1.335

Warning: Covariance matrix could not be computed because the finite-difference Hessian was indefinite. Analysis completed  $21$ -Mar-2004 00:12. Runtime = 0.06 seconds.

---- Descriptive Statistics for Variables ----



---- Calculated Parameter Values ----



Nortriptyline 1%, 0.4 mA/cm^2

---- Analysis of Variance ----



1: Title "Aqueous layer equation"; 2: Variable time; // Cooling time in hr 3: Variable Qa; // Quantity thru skin in micrograms 4: Constant L=500\*10^-4; // Skin thickness in cm // Diffusion coefficient in aqueous layer 5: Parameter Da; 6: Parameter C1; // Bulk concentration 7: Function Qa= C1\*L\* (Da\*time/L^2-1/6-2/pi^2\* (cos (pi)\*exp(-Da\*pi^2\*time/L^2)+cos(pi\*2)/4\*exp(-Da\*4\*pi^2\*time/L^2)+cos(pi\*3)/9\*exp(- $Da*9*pi^2*time/L^2))$ ; 8: Plot xlabel="Time (hr)", ylabel="Drug permeated (micrograms)";  $9: Data;$ Beginning computation... Stopped due to: Relative function convergence.  $---$  Final Results  $---$ NLREG version 6.1 Copyright (c) 1992-2004 Phillip H. Sherrod. Aqueous layer equation Number of observations =  $9$ Maximum allowed number of iterations = 500 Convergence tolerance factor =  $1.000000E-010$ Stopped due to: Relative function convergence. Number of iterations performed =  $272$ Final sum of squared deviations =  $4.8650395E+003$ Final sum of deviations =  $3.3538052E+001$ Standard error of estimate = 26.363 Average deviation =  $20.9638$ Maximum deviation for any observation = 34.8249 Proportion of variance explained  $(R^2) = 0.9912$  (99.12%) Adjusted coefficient of multiple determination  $(Ra^2) = 0.9900$  (99.00%) Durbin-Watson test for autocorrelation =  $1.284$ 

Warning: Covariance matrix could not be computed because the finite-difference Hessian was indefinite. Analysis completed  $21$ -Mar-2004 00:13. Runtime = 0.05 seconds.

---- Descriptive Statistics for Variables ----



---- Calculated Parameter Values ----

Parameter Initial guess Final estimate <u>------------------</u> --------------**.................** 



---- Analysis of Variance ----



## **Nortriptyline Control**

1: Title "Aqueous layer equation"; 2: Variable time; // Cooling time in hr 3: Variable Qa; // Quantity thru skin in micrograms // Skin thickness in cm 4: Constant L=500\*10^-4; // Diffusion coefficient in aqueous layer 5: Parameter Da; 6: Parameter C1; // Bulk concentration 7: Function Qa= C1\*L\* (Da\*time/L^2-1/6-2/pi^2\* (cos (pi) \*exp (-Da\*pi^2\*time/L^2)+cos(pi\*2)/4\*exp(-Da\*4\*pi^2\*time/L^2)+cos(pi\*3)/9\*exp(- $Da*9*pi^2*time/L^2))$ ; 8: Plot xlabel="Time (hr)", ylabel="Drug permeated (micrograms)";  $9: Data;$ Beginning computation... Error executing line 7: Function Qa= C1\*L\* (Da\*time/L^2-1/6-2/pi^2\* (cos(pi)\*exp(-Da\*pi^2\*time/L Error: Argument to exp function is too large (1315.22) Error executing line 7: Function Qa=  $Cl^{\star}L^{\star}$  (Da\*time/L^2-1/6-2/pi^2\* (cos(pi)\*exp(-Da\*pi^2\*time/L Error: Argument to exp function is too large (2959.25) Stopped due to: Relative function convergence.  $---$  Final Results  $---$ NLREG version 6.1 Copyright (c) 1992-2004 Phillip H. Sherrod. Aqueous layer equation Number of observations =  $9$ Maximum allowed number of iterations =  $500$ Convergence tolerance factor =  $1.000000E-010$ Stopped due to: Relative function convergence. Number of iterations performed =  $184$ Final sum of squared deviations =  $1.0144198E+001$ Final sum of deviations =  $6.1097103E-001$ Standard error of estimate =  $1.20382$ Average deviation =  $0.909294$ Maximum deviation for any observation = 1.74446 Proportion of variance explained  $(R^2) = 0.9890$  (98.90%) Adjusted coefficient of multiple determination  $(Ra^2) = 0.9875$  (98.75%) Durbin-Watson test for autocorrelation = 0.943 Analysis completed  $21$ -Mar-2004 00:15. Runtime = 0.06 seconds.

---- Descriptive Statistics for Variables ----



---- Calculated Parameter Values ----



# ---- Analysis of Variance ----



# **REFERENCES**

- 1. B. Barry, Dematological formulations: Percutaneous absorption, Marcel Dekker, Inc., New York, 1983.
- 2. J. Bouwstra, B. A. I. van den Bergh, M. Suhonen, Topical Application of Drugs: Mechanisms Involved in Chemical Enhancement, H. Schreier, Ed., Drug Targeting Technology, Marcel Dekker, Inc., New York, 2001.
- 3. R. Burkman, The transdermal contraceptive system, American Journal of Obstetrics and Gynecology, 190 (2004) S49-53.
- 4. J. Du Plessis, W. J. Pugh, A. Judefeind, J. Hadgraft, The effect of the nature of Hbonding roups on diffusion through PDMS membranes saturated with octanol and toluene, European Journal of Pharmaceutical Sciences 15 (2002) 63-69.
- 5. D. A. Essa, M. C. Bonner, B. W. Barry, Electrically assisted skin delivery of liposomal estadiol; phospholipids as damage retardant, Journal of Controlled Release 95 (2004) 535-546.
- 6. J. Y. Fang, K. C. Sung, H. H. Lin, C. L. Fang, Transdermal iontophoretic delivery of diclofenac sodium from various polymer formulations: in vitro and in vivo studies, International Journal of Pharmaceutics 178 (1999) 83-92.
- 7. A. M. de Graaff, G. L. Li, A. C. van Aelst, J. A. Bouwstra, Combined chemical and electrical enhancement modulates stratum corneum structure, Journal of Controlled Release 90 (2003) 49-58.
- 8. J. Hadgraft, Skin, the final frontier, International Journal of Pharmaceutics 224 (2201) 1-18.
- 9. J. E. Harrison, A. C. Watkinson, D. M. Green, J. Hadgraft, K. Brian, The Relative Effect of Azone® on Permeant Diffusivity and Solubility in Human Stratum Corneum, Pharmaceutical Research 12 (1996) 542-546.
- 10. J. Hirvonene, L. Murtomäki, K. Konttun, Experimental verification of the mechanistic model for transdermal transport including iontophoresis, Journal of Controlled Release 56 (1998) 168-174.
- 11. H. E. Junginger, Iontophoretic delivery of apomorphine: from in-vitro modeling to the Parkinson patient, Advanced Drug Delivery Reviews 54 Suppl. 1 (2002) S57-S75.
- 12. K. Kontturi and L. Murtomäki, Mechanistic model for transdermal transport including iontophoresis, Journal of Controlled Release 41 (1996) 177-185.
- 13. K. Kubota, F. Dey, S. A. Matar, E. H. Twizell, A repeated-dose model of percutaneous drug absorption, Applied Mathematical Modelling 26 (2002) 529-544.
- 14. A. J. Lee, J. R. King, T. G. Rogers, A multiple-pathway model for the diffusion of drugs in skin, Journal of Mathematics Applied in Medicine and Biology 13 (1996) 127-150.
- 15. A. J. Lee, J. R. King, D. A. Barrett, Percutaneous absorption: a multiple pathway model, Journal of Controlled Release 45 (1997) 141-151.
- 16. J. K. W. Lee, A. A. Aldama, Multipath diffusion: A general numerical model, Computers & Geosciences 18 (1992) 531-555.
- 17. C. P. Lim, S. S. Quek, K. K. Peh, Prediction of drug release profiles using an intelligent learning system: an experimental study in transdermal iontophoresis, Journal of Pharmaceutical and Biomedical Analysis 31 (2003), 159-168.
- 18. V. M. Meidan, M. Al-Khalili, B. B. Michniak, Enhanced iontophoretic delivery of busipirone hydrochloride across human skin using chemical enhancers, International Journal of Pharmaceutics 264 (2003) 73-83.
- 19. S. Mitragotri, Modeling skin permeability to hydrophilic and hydrophobic solutes based on four permeation pathways, Journal of Controlled Release 86 (2003) 69-92.
- 20. K. Moser, K. Kriwet, A. Naik, Y. N. Kalia, R. H. Guy, Passive skin penetration enhancement and its quantification in vitro, European Journal of Pharmaceutics and Biopharmaceutics 52 (2001) 103-112.
- 21. V. B. Nair , R. Panchagnula, Effect of iontophoresis and fatty acids on permeation of Arginine Vasopressin through rat skin, Pharmacological Research 47 (2003) 563-569.
- 22. J. Pieper, G. Charalambopoulou, Th. Stenotis, S. Vasenkov, A. Desmedt, R. E. Lechner, Water diffusion in fully hydrated porcine stratum corneum, Chemical Physics 292 (2003) 467-476.
- 23. M. J. Pikal, The role of electroosmotic flow in transdermal iontophoresis, Advanced Drug Delivery Reviews 46 (2001) 281-305.
- 24. Y. Wang, Q. Fan, Y. Song, B. Michniak, Effects of fatty acids and iontophoresis on the delivery of midodrine hydrochlonde and the structure of human skin, Pharmaceutical Research 20 (2003) 1612-1618.
- 25. Y. Wang, Transdermal delivery of tricyclic antidepressants using iontophoresis and chemical enhancers, Ph.D. Thesis, Ernest Mario School of Pharmacy, Rutgers — The State University of New Jersey, 2004.